<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nanobiomedicine (Rij)</journal-id><journal-id journal-id-type="iso-abbrev">Nanobiomedicine (Rij)</journal-id><journal-id journal-id-type="publisher-id">NAB</journal-id><journal-id journal-id-type="hwp">spnab</journal-id><journal-title-group><journal-title>Nanobiomedicine</journal-title></journal-title-group><issn pub-type="epub">1849-5435</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6029241</article-id><article-id pub-id-type="doi">10.5772/58841</article-id><article-id pub-id-type="publisher-id">10.5772_58841</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title>Engineering Iron Oxide Nanoparticles for Clinical Settings</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cortajarena</surname><given-names>Aitziber L.</given-names></name><xref ref-type="aff" rid="aff1-58841">1</xref><xref ref-type="aff" rid="aff2-58841">2</xref><xref ref-type="other" rid="equal1-58841">&#x003b6;</xref></contrib><contrib contrib-type="author"><name><surname>Ortega</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff1-58841">1</xref><xref ref-type="aff" rid="aff2-58841">2</xref><xref ref-type="aff" rid="aff3-58841">3</xref><xref ref-type="other" rid="equal1-58841">&#x003b6;</xref></contrib><contrib contrib-type="author"><name><surname>Ocampo</surname><given-names>Sandra M.</given-names></name><xref ref-type="aff" rid="aff1-58841">1</xref><xref ref-type="other" rid="equal1-58841">&#x003b6;</xref></contrib><contrib contrib-type="author"><name><surname>Gonzalez-Garc&#x000ed;a</surname><given-names>Alberto</given-names></name><xref ref-type="aff" rid="aff1-58841">1</xref></contrib><contrib contrib-type="author"><name><surname>Couleaud</surname><given-names>Pierre</given-names></name><xref ref-type="aff" rid="aff1-58841">1</xref><xref ref-type="aff" rid="aff2-58841">2</xref></contrib><contrib contrib-type="author"><name><surname>Miranda</surname><given-names>Rodolfo</given-names></name><xref ref-type="aff" rid="aff1-58841">1</xref></contrib><contrib contrib-type="author"><name><surname>Belda-Iniesta</surname><given-names>Cristobal</given-names></name><xref ref-type="aff" rid="aff1-58841">1</xref><xref ref-type="aff" rid="aff4-58841">4</xref><xref ref-type="aff" rid="aff5-58841">5</xref></contrib><contrib contrib-type="author"><name><surname>Ayuso-Sacido</surname><given-names>Angel</given-names></name><xref ref-type="aff" rid="aff1-58841">1</xref><xref ref-type="aff" rid="aff4-58841">4</xref><xref ref-type="corresp" rid="corresp1-58841">*</xref></contrib></contrib-group><aff id="aff1-58841"><label>1</label> Instituto Madrile&#x000f1;o de Estudios Avanzados IMDEA-Nanociencia, Madrid, Spain</aff><aff id="aff2-58841"><label>2</label> Centro Nacional de Biotecnolog&#x000ed;a (CNB-CSIC) - IMDEA Nanociencia Associated Unit &#x0201c;Unidad de Nanobiotecnolog&#x000ed;a&#x0201d;, Cantoblanco, Madrid, Spain</aff><aff id="aff3-58841"><label>3</label> Institute of Biomedical Engineering, University College London, UK</aff><aff id="aff4-58841"><label>4</label> Centro Integral Oncol&#x000f3;gico Clara Campal (CIOCC) and Instituto de Medicina Molecular Aplicada (IMMA). Hospital de Madrid Foundation, Madrid, Spain</aff><aff id="aff5-58841"><label>5</label> National School of Health, ISCIII, Madrid, Spain</aff><author-notes><corresp id="corresp1-58841"><label>*</label> Corresponding author E-mail: <email xlink:href="ayusosacido@fundacionhm.com">ayusosacido@fundacionhm.com</email></corresp><fn fn-type="equal" id="equal1-58841"><label>&#x003b6;</label><p>Equal contribution</p></fn></author-notes><pub-date pub-type="epub"><day>1</day><month>1</month><year>2014</year></pub-date><pub-date pub-type="collection"><season>Jan-Dec</season><year>2014</year></pub-date><volume>1</volume><elocation-id>2</elocation-id><history><date date-type="received"><day>22</day><month>4</month><year>2014</year></date><date date-type="accepted"><day>1</day><month>7</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; 2014 The Author(s). Licensee InTech.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</copyright-holder><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0">http://creativecommons.org/licenses/by/3.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Iron oxide nanoparticles (IONPs) occupy a privileged position among magnetic nanomaterials with potential applications in medicine and biology. They have been widely used in preclinical experiments for imaging contrast enhancement, magnetic resonance, immunoassays, cell tracking, tissue repair, magnetic hyperthermia and drug delivery. Despite these promising results, their successful translation into a clinical setting is strongly dependent upon their physicochemical properties, toxicity and functionalization possibilities. Currently, IONPs-based medical applications are limited to the use of non-functionalized IONPs smaller than 100 nm, with overall narrow particle size distribution, so that the particles have uniform physical and chemical properties. However, the main entry of IONPs into the scene of medical application will surely arise from their functionalization possibilities that will provide them with the capacity to target specific cells within the body, and hence to play a role in the development of specific therapies. In this review, we offer an overview of their basic physicochemical design parameters, giving an account of the progress made in their functionalization and current clinical applications. We place special emphasis on past and present clinical trials.</p></abstract><kwd-group><kwd>Iron Oxide Nanoparticles</kwd><kwd>IONP</kwd><kwd>SPION</kwd><kwd>USPION</kwd><kwd>VSPION</kwd><kwd>Drug Delivery</kwd><kwd>Magnetic Hyperthermia</kwd><kwd>MRI</kwd><kwd>Nanomedicine</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="section1-58841"><title>1. Introduction</title><p>Over the last decade, nanotechnology has become more relevant in many industrial sectors, including medicine. In general, the future projection and promotion of iron oxide nanoparticles (IONPs) as a point of reference among other magnetic nanomaterials for clinical applications relies chiefly on their biocompatibility in moderate doses, their relatively well-known iron metabolic pathways and their ability to be produced in a wide range of sizes and shapes with biofunctionalization potential. Additionally, the added advantage of magnetic actuation makes IONPs stand out from many other nanotechnology-based therapeutic and diagnostic approaches. In any case, IONPs have already passed through the preclinical stage to become a reality in clinical practice. In particular, they improve imaging-based diagnostics of immunological diseases, cardiovascular and cerebrovascular pathologies and cancer. They show great promise to serve as a cell tracking system in cell-based therapies, and to generate local temperature increases in the magnetic thermotherapy of solid tumours.</p><p>The purpose of this work is to review the basic parameters involved in the design of IONPs and their functionalization possibilities which, in the next few years, will bring into being a completely new generation of IONPs with selective targeting properties. Functionalized and multifunctionalized IONPs will become nanocarriers that will improve the selectivity of specific cells and, therefore, allow for the development of specific therapies. We describe their biochemical features, their cell internalization and <italic>in vivo</italic> administration, as well as the reduced toxicology effects that have contributed to their successful use in current clinical applications. Additionally, we discuss most of the past and present clinical trials involving IONPs, placing special emphasis on their interactions with different compartments of the immune system. Finally, we highlight the potential advances in functionalization and magnetic hyperthermia as two fields that will surely push forward the clinical use of IONPs.</p></sec><sec id="section2-58841"><title>2. Basic physicochemical characteristics of IONPs</title><sec id="section3-58841"><title>2.1 Size</title><p>This is arguably the most important parameter upon which any IONPs system must be designed. First, it profoundly affects the dynamics of the magnetic moments in magnetic NPs&#x02014;also regarded as the magnetic <italic>relaxation processes</italic>&#x02014;that also depend on other parameters, such as temperature or externally applied magnetic fields. Second, particle size is of paramount importance in the detection, internalization and eventual fate of IONPs inside mammalians.</p><p>Two of the most relevant magnetic scale lengths that characterize magnetic NP systems are the superparamagnetic radius (<italic>RSPM</italic>) and the single domain radius (<italic>RSD</italic>). <italic>RSPM</italic> refers to the maximum particle size up to which a superparamagnetic regime is observed. <italic>RSD</italic> indicates the value below which the formation of magnetic domains&#x02014;regions grouping magnetic moments with the same orientation&#x02014;is no longer energetically favourable and indicates that the most stable magnetic configuration for the particle is the single domain state [<xref rid="bibr1-58841" ref-type="bibr">1</xref>]. Both <italic>RSD</italic> and <italic>RSPM</italic> can be worked out from the anisotropy constant (<italic>K</italic>), the dimensionless hardness parameter (&#x003ba;) and the exchange stiffness constant (<italic>A</italic>) [<xref rid="bibr2-58841" ref-type="bibr">2</xref>] of the material of interest. <xref rid="table1-58841" ref-type="table">Table 1</xref> summarizes these parameters for maghaemite and magnetite, the most commonly used iron oxides in biomedicine, and gives a glimpse of the range of magnetic behaviours of IONPs with varying particle size.</p><table-wrap id="table1-58841" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Characteristic magnetic length scales for the most relevant iron oxides [<xref rid="bibr123-58841" ref-type="bibr">123</xref>][<xref rid="bibr124-58841" ref-type="bibr">124</xref>][<xref rid="bibr125-58841" ref-type="bibr">125</xref>]. Data for iron are included for comparison.</p></caption><alternatives><graphic xlink:href="10.5772_58841-table1"/><table frame="border" rules="all" width="100%"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1"/><th align="center" rowspan="1" colspan="1">K</th><th align="center" rowspan="1" colspan="1">A</th><th align="center" rowspan="1" colspan="1">MS</th><th align="center" rowspan="2" colspan="1">k</th><th align="center" rowspan="1" colspan="1">lex</th><th align="center" rowspan="1" colspan="1">Rsd</th><th align="center" rowspan="1" colspan="1">Rspm</th></tr><tr><th align="center" rowspan="1" colspan="1">(J/m3)</th><th align="center" rowspan="1" colspan="1">(J/m)</th><th align="center" rowspan="1" colspan="1">(A/m)</th><th align="center" rowspan="1" colspan="1">(nm)</th><th align="center" rowspan="1" colspan="1">(nm)</th><th align="center" rowspan="1" colspan="1">(nm)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Maghemite</td><td align="center" rowspan="1" colspan="1">4.6&#x000d7;10<sup>3</sup></td><td align="center" rowspan="1" colspan="1">&#x0223c;10<sup>&#x02212;11</sup></td><td align="center" rowspan="1" colspan="1">3.8&#x000d7;10<sup>5</sup></td><td align="center" rowspan="1" colspan="1">0.16</td><td align="center" rowspan="1" colspan="1">7.4</td><td align="center" rowspan="1" colspan="1">42.5</td><td align="center" rowspan="1" colspan="1">17.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Magnetite</td><td align="center" rowspan="1" colspan="1">1.35&#x000d7;10<sup>4</sup></td><td align="center" rowspan="1" colspan="1">133&#x000d7;10<sup>&#x02212;11</sup></td><td align="center" rowspan="1" colspan="1">4.8&#x000d7;10<sup>5</sup></td><td align="center" rowspan="1" colspan="1">0.21</td><td align="center" rowspan="1" colspan="1">6.8</td><td align="center" rowspan="1" colspan="1">52.7</td><td align="center" rowspan="1" colspan="1">12.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Iron</td><td align="center" rowspan="1" colspan="1">4.8&#x000d7;10<sup>4</sup></td><td align="center" rowspan="1" colspan="1">1.49&#x000d7;10<sup>&#x02212;11</sup></td><td align="center" rowspan="1" colspan="1">1.71&#x000d7;10<sup>6</sup></td><td align="center" rowspan="1" colspan="1">0.11</td><td align="center" rowspan="1" colspan="1">2.0</td><td align="center" rowspan="1" colspan="1">8.3</td><td align="center" rowspan="1" colspan="1">8.0</td></tr></tbody></table></alternatives></table-wrap><p>IONPs may be produced by a number of methods that allow for precise control over their size, shape and surface chemistry [<xref rid="bibr3-58841" ref-type="bibr">3</xref>][<xref rid="bibr4-58841" ref-type="bibr">4</xref>][<xref rid="bibr5-58841" ref-type="bibr">5</xref>][<xref rid="bibr6-58841" ref-type="bibr">6</xref>]. These parameters, along with others, can be used to classify IONPs for different purposes [<xref rid="bibr7-58841" ref-type="bibr">7</xref>]. With reference to particle size, the researchers working on IONPs in medicine and biology&#x02014;especially in the MRI community&#x02014;use an informal classification divided into distinct ranges as follows: below 10 nm, very small superparamagnetic iron oxide NPs (VSPIONs); between 10 and 50 nm, ultrasmall superparamagnetic iron oxide NPs (USPIONs); and between 50 and 180 nm, superparamagnetic iron oxide NPs (SPIONs).</p><p>Although this classification might be useful only for the purpose of gathering some size ranges showing similar circulation and relaxational properties for specific applications, IONPs are persistently referred to in the literature as SPIONs, regardless of their true magnetic properties. This misuse of the term SPION is both inaccurate and confusing, as the lower-end value of the SPIONs' size range lies at the theoretical transition between superparamagnetic and single domain states for iron oxides (<xref rid="table1-58841" ref-type="table">Table 1</xref>). Thus, most of the particle sizes encompassed within this range would in fact be single domain, not superparamagnetic. Interparticle interactions and surface effects further complicate this picture by shifting <italic>RSPM</italic> away from its theoretical value. Therefore, we recommend avoiding, where possible, the SPION-based nomenclature and using a more general one describing the actual behaviour of the IONPs experimentally characterized by magnetic measurements, either: (i) based on size effects (superparamagnetic, single domain and multidomain) or (ii) on the coupling between magnetic moments (ferro-, ferri-, or antiferromagnetic, as applicable). Another source of confusion is the conflation of the numerical size values measured by different techniques, more specifically the &#x0201c;physical&#x0201d; size&#x02014;typically obtained through electron microscopy, X-ray diffractometry, or similar means&#x02014;and the <italic>hydrodynamic size</italic>&#x02014;measured by dynamic light scattering or acoustic spectroscopy, and a value that, besides the physical particle size, also takes into account the thickness of any coating agent and the solvation molecules from the solvent. A final word of caution in this regard is that many IONPs are prepared by forming aggregates of variable size instead of a dispersion of single NPs; the size of the aggregates&#x02014;often referred to as <italic>multi-cores</italic>&#x02014;and that of the single particles are sometimes carelessly conflated.</p><p>From a biological point of view, IONPs can travel anywhere through the circulatory system of the human body, since the smallest capillaries are 4&#x02013;6 &#x003bc;m wide [<xref rid="bibr8-58841" ref-type="bibr">8</xref>]. IONPs under 100 nm are considered to be suitable for any application requiring tissue penetration, but those around 5 nm are more effective for tumour penetration [<xref rid="bibr9-58841" ref-type="bibr">9</xref>]. Nonetheless, at the cellular level, NP size also influences the binding affinity of molecules, the uptake of additional particles into the cell, and the actual location within the cell. For a given NP shape, there is an optimal size for NP diffusion through the potential barrier characterizing the particle&#x02013;cell interaction, as found by theoretical models [<xref rid="bibr10-58841" ref-type="bibr">10</xref>][<xref rid="bibr11-58841" ref-type="bibr">11</xref>]. Numerical calculations of these models indicate that the optimal NP size for a reasonably quick endocytosis is somewhere around 25 to 35 nm. Regardless of the particular considerations in each of the proposed models, the aforementioned optimum size range is given by the interplay between the kinetics and thermodynamics of the diffusion&#x02013;absorption process of NPs relative to the thermal energy involved. Of particular note is that within the framework of the model proposed by Shi <italic>et al.</italic>, the optimum particle sizes obtained do not depend on the absorption coefficient, the viscosity of the medium, or the cell size [<xref rid="bibr10-58841" ref-type="bibr">10</xref>] (<xref ref-type="fig" rid="fig1-58841">Figure 1</xref>).</p><fig id="fig1-58841" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Membrane deformation for (a) shallow wrapping and (b) deep wrapping of a cubic-shaped nanoparticle. The network of edges and triangles describes the membrane shape and has been used for the numerical calculation of the curvature energy. [Adapted with permission from S. Dasgupta, <italic>et al., Nano Letters</italic> 14(2) (2014) 687&#x02013;693. Copyright 2014 American Chemical Society]. (c) Values of diffusion length (<italic>l<sub>diff</sub></italic>) of nanoparticles as a function of particle size (<italic>R</italic>) at fixed values of aspect ratio (<italic>a</italic>) [Reprinted with permission from X. Li, <italic>Journal of Applied Physics</italic>, vol. 111 (2012) 024702. Copyright 2012, AIP Publishing LLC]. (d) Normalized absorption rate of cylindrical particles with different diameters and aspect ratios [Permission pending].</p></caption><graphic xlink:href="10.5772_58841-fig1"/></fig></sec><sec id="section4-58841"><title>2.2 Shape</title><p>Consider a magnetic particle as composed of many positive and negative poles; these will cancel each other, but there will still be free poles at the surface of the particle. These free poles create a magnetic field&#x02014;the demagnetizing field (<italic>H<sub>d</sub></italic>)&#x02014;that depends on the particle shape and is opposed to the direction of the external field (<italic>H<sub>ext</sub></italic>). It follows that the effective magnetic field (<italic>H<sub>eff</sub></italic>) acting on a particle will be different from <italic>H<sub>ext</sub></italic>:<italic>H<sub>eff</sub> = H<sub>ext</sub> -H<sub>d</sub></italic>, where <italic>H<sub>d</sub> = N&#x000b7;M</italic>, with <italic>M</italic> the magnetization of the particle and <italic>N</italic> the so-called demagnetizing factor (<italic>N</italic>). In the case of a spherical shape, <italic>N</italic> = 1 due to the even distribution of free poles over the particle's surface. Other morphologies different from a perfect sphere&#x02014;the usual case in many real systems&#x02014;may be approximated to distorted ellipsoids. In this way, the anisotropy energy associated with the shape of an ellipsoidal particle with its major axis lying along the <italic>z</italic> direction equals [<xref rid="bibr12-58841" ref-type="bibr">12</xref>]: <italic>E<sub>shape</sub></italic> = [<italic>&#x003bc;0MS</italic><sup>2</sup>(<italic>N<sub>x</sub>-N<sub>z</sub>)/</italic>2]<sup>&#x02212;1</sup>, where <italic>MS</italic> is the saturation magnetization and <italic>&#x003bc;0</italic> is the permeability of the free space.</p><p>Besides its contribution to the total anisotropy energy of magnetic particles, the role of the particle shape in the magnetic properties of NPs is linked to the stability of the single domain configuration. For example, disc-like NPs with relatively higher aspect ratios may show a closed spiral arrangement of their magnetic moments [<xref rid="bibr13-58841" ref-type="bibr">13</xref>], called a <italic>vortex</italic> state, whereas particles with the same shape but lower aspect ratios show the typical parallel arrangement of moments commonly seen in uniformly magnetized single domain NPs [<xref rid="bibr14-58841" ref-type="bibr">14</xref>].</p><p>On the biological side, the shape of an NP determines the extent to which the NP will interact with membrane receptors and hence the degree of internalization. Shi <italic>et al.</italic> modelled the particle&#x02013;cell interaction by considering the diffusion and absorption of rod-like (cylindrical) and spherical NPs through a partially absorbing spherical cell [<xref rid="bibr15-58841" ref-type="bibr">15</xref>]. For a fixed set of physical parameters of the particles, cell and medium, numerical results show that for each NP size there is a specific aspect ratio value for which the absorption rate is maximum (red region in <xref ref-type="fig" rid="fig2-58841">Figure 2A</xref>), demonstrating the joint relevance of the size and shape of NPs to their internalization. Strange as it may seem, the outcomes of this work also suggest that the optimum particle size and shape for endocytosis do not depend noticeably on either the particular NP's absorption mechanism or the viscosity of the medium. Subsequent models based on similar grounds coincide in more general aspects. Noticeably, in particles with increasing aspect ratios, endocytosis becomes energetically favourable with decreasing particle sizes (<xref ref-type="fig" rid="fig2-58841">Figure 2B</xref>). Particle orientation adds to the intricate influence of particle shape. Recent theoretical calculations based on membrane mechanics show how possible particle wrapping states&#x02014;designated as <italic>shallow</italic> (<xref ref-type="fig" rid="fig2-58841">Figure 2C</xref>) and <italic>deep</italic> (<xref ref-type="fig" rid="fig2-58841">Figure 2D</xref>)&#x02014;evolve, depending on the particle aspect ratio and edge curvature [<xref rid="bibr16-58841" ref-type="bibr">16</xref>]. The proposed model predicts that particles with a high aspect ratio and round tips enter the cell membrane with their long edge parallel to the membrane, whereas those with low aspect ratio and sharp edges proceed tip-first. Despite its intrinsic limitations, this model provides the basis for making predictions of particle toxicity considering particles' shape and wrapping degree. Other studies on the interaction between other types of nanostructures, like nanosheets or nanotubes, and cell membranes have been reviewed elsewhere [<xref rid="bibr17-58841" ref-type="bibr">17</xref>]. Although some of the results reported for these nanostructures sharply differ from those for NPs, many others are consonant; for instance, some aspects relating to the uptake mechanism of nanotubes and elongated NPs with variable edge curvature [<xref rid="bibr17-58841" ref-type="bibr">17</xref>][<xref rid="bibr18-58841" ref-type="bibr">18</xref>]. Finally, the circulation and the eventual <italic>in vivo</italic> fate of IONPs inside the body are also determined by particle shape to a great extent [<xref rid="bibr19-58841" ref-type="bibr">19</xref>].</p><fig id="fig2-58841" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Schematic representation of the theoretical magnetic regimes (superparamagnetic, single domain, multidomain) expected for both magnetite and maghaemite, along with some relevant applications as a function of the particle size. (*) Magnetofection is a trademark of Christian Bergemann and Dr Christian Plank. (**) Refers to uncoated, single nanoparticles. The size ranges represented are approximate and comprise the most common cases.</p></caption><graphic xlink:href="10.5772_58841-fig2"/></fig></sec><sec id="section5-58841"><title>2.3 Surface charge density</title><p>An additional degree of complexity linked to the biological activity of NPs is constituted by their effective superficial charge, which determines the type of active or passive functionalization through specific molecules and the relevant particle&#x02013;cell interaction mechanisms, which is revisited in the following sections. In this regard, the magnetic properties of NPs would remain virtually unaffected by their surface charge, even though the coating used to tune the surface charge or the affinity for a particular target may introduce sizeable modifications, as discussed later. As a first approximation, bare IONPs possess a surface charge strongly influenced by the environment, involving the pH and the ionic strength of the medium. The point of zero charge (PZC), that is, the pH values for which the surface charge density is zero, for bare IONPs may span several pH units depending on the type and concentration of charged species in the medium. For magnetite, it has been reported to range between 3.9 and 9.9 [<xref rid="bibr20-58841" ref-type="bibr">20</xref>], and for maghaemite the reported range is around 3.3&#x02013;7.5 depending on the reaction conditions [<xref rid="bibr21-58841" ref-type="bibr">21</xref>]. Besides the PZC, another surface charge parameter of interest is the zeta-potential (&#x003b6;) [<xref rid="bibr22-58841" ref-type="bibr">22</xref>][<xref rid="bibr23-58841" ref-type="bibr">23</xref>], whose sign and value give an idea of the colloidal stability of NP suspensions rather than focusing exclusively on the isolated particles. It is commonly accepted that a stable colloidal suspension of IONPs has approximately &#x003b6; &#x0003c; &#x02212;30 mV or &#x003b6; &#x0003e; +30 mV. Nevertheless, bare IONPs as such are of very limited interest for biomedical applications, due to their non-specificity, tendency to aggregation and short circulation times, as well as their toxicity, since they may induce vacuole formation and other cell damage leading to cell death [<xref rid="bibr24-58841" ref-type="bibr">24</xref>]. In order to manipulate the surface charge, improve their biocompatibility and/or add a specific functionality (see <xref ref-type="sec" rid="section2-58841">section 2</xref>), IONPs can be coated with a large number of molecules by virtue of their relatively wide PZC range discussed above.</p><p>The surface charge of both bare and coated IONPs influences the binding to cell membranes as the limiting step in their internalization process [<xref rid="bibr25-58841" ref-type="bibr">25</xref>], irrespective of the shape. It is rather the sign of the charge that determines the internalization mechanism [<xref rid="bibr26-58841" ref-type="bibr">26</xref>]. Membrane interaction can occur regardless of the charge of NPs, but it is well known that positively- or negatively-charged IONPs are internalized more rapidly than neutral ones. For instance, <italic>in vitro</italic> studies with L929 fibroblasts and Saos-2 osteoblasts reveal how the uptake of negatively-charged SPIONs (coated with dimercaptosuccinic acid, DMSA) and positively-charged SPIONs (coated with (3-aminopropyl) triethoxysilane, APS) is far superior to that of neutral SPIONs (coated with dextran) [<xref rid="bibr27-58841" ref-type="bibr">27</xref>]. This charge-mediated internalization enhancement may lead to cell damage for concentrations of DMSA and APS-coated SPIONs above 0.10 mg/mL in L929 fibroblasts and 0.20 mg/mL in Saos-2 osteoblasts. Mahmoudi <italic>et al</italic> have found that positively-charged SPIONs promote amyloid-&#x003b2; protein fibrillation at significantly lower particle concentrations than neutral or negatively-charged SPIONs [<xref rid="bibr28-58841" ref-type="bibr">28</xref>].</p><p>A good example of how surface charge may affect the fate of similar IONPs formulations inside mammalians arises from the comparison of ferumoxides (&#x003b6; = &#x02212;32 mV), ferumoxytol (&#x003b6; = &#x02212;49 mV) and ferumoxtran (&#x003b6; = &#x02212;2 to 0 mV). The latter has a thicker dextran layer [<xref rid="bibr29-58841" ref-type="bibr">29</xref>] to avoid opsonization (protein adsorption) typically seen in very small particles and increase its circulation time, but in exchange is internalized to a lesser extent due to its almost neutral &#x003b6;. On the other hand, ferumoxides and ferumoxytol do not adsorb proteins and do not readily become opsonized, but are removed from circulation by the reticuloendothelial (RES) system due to their negative &#x003b6;.</p></sec></sec><sec id="section6-58841"><title>3. Functionalization of IONPs</title><p>Functionalization of IONPs with biomolecules is a subject of great interest for two aspects related to their clinical applications. First, IONPs can be used as nanocarriers for drug delivery to tackle drug resistance of cancer cells and to increase local drug concentrations. Second, IONPs can be functionalized with specific targeting agents in order to improve the selectivity of specific cells, such as cancer cells, and therefore improve the selectivity, reduce side effects and increase local concentrations of drugs and/or IONPs in the targeted tissue. All these strategies are involved in the development of new generations of functionalized and multifunctionalized NPs for biomedical applications that introduce selective targeting properties to such nanocarriers.</p><p>The effect of targeting is strongly related to the enhancement of cellular uptake. Indeed, targeting strategies involve the recognition and binding to membrane receptors overexpressed on targeted cells, which changes the cellular uptake pathway and its efficiency. Several functionalization and targeting strategies have been developed in parallel with the latest advances in the discovery of new biomarkers specific to the different types of cells considered (e.g., cancer cells, cancer stem cells, etc.).</p><p>Currently, no clinical trials are in progress concerning the use of functionalized IONPs in humans. However, almost all the scientific publications in the field mention the potential biomedical and clinical applications of functionalized IONPs considering the promising <italic>in vitro</italic> and <italic>in vivo</italic> results. Among the wide diversity of molecules that have been used for the functionalization of IONPs described hereafter, most are already accepted by the different drug regulation administrations or are now in late clinical trial phases. Similarly, the IONP-based formulations ferumoxytol and GastroMARK are also approved. Therefore, the combination of both IONPs and specific functionalities shows great potential in the near future for the generation of novel nanoformulations for clinical use.</p><p>Here, we present an overview of the different molecules that are currently used for the functionalization of IONPs, highlighting some relevant examples and their potential in clinics (<xref rid="table2-58841" ref-type="table">Table 2</xref> and <xref ref-type="fig" rid="fig3-58841">Figure 3</xref>).</p><table-wrap id="table2-58841" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Examples of biomolecules approved for clinical applications or already in clinical trials that are used in IONPs functionalization research studies</p></caption><alternatives><graphic xlink:href="10.5772_58841-table2"/><table frame="border" rules="all" width="100%"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Type of biomolecule</th><th align="center" rowspan="1" colspan="1">Used name</th><th align="center" rowspan="1" colspan="1">Biological Target</th><th align="center" rowspan="1" colspan="1">Clinical trials status</th><th align="center" rowspan="1" colspan="1">Remarks and references of IONPs functionalization in research studies</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Cell Penetrating Peptides (CPPs)</td><td align="center" rowspan="1" colspan="1">p28 (azurin fragment)</td><td align="center" rowspan="1" colspan="1">DNA binding domain of p53</td><td align="center" rowspan="1" colspan="1">p28 alone in phase I (NCT01975116 and NCT00914914)</td><td align="center" rowspan="1" colspan="1">No research studies with IONPs</td></tr><tr><td align="center" rowspan="4" colspan="1">Small Peptides</td><td align="center" rowspan="1" colspan="1">Arginine-Glycine-Aspartic acid (RGD)</td><td align="center" rowspan="1" colspan="1">Integrin receptor &#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub></td><td align="center" rowspan="1" colspan="1">Phase I/II for cancer diagnostic by positron emission tomography<break/>(NCT01806675, NCT00565721, NCT01492192, NCT01961583)</td><td align="center" rowspan="1" colspan="1">Montet et al. 2006 Xie et al. 2008 Nazli et al. 2012</td></tr><tr><td align="center" rowspan="2" colspan="1">Chlorotoxin (CTX)</td><td align="center" rowspan="2" colspan="1">Binding affinity for gliomas and neuroectodermal tumors</td><td align="center" rowspan="1" colspan="1">Phase I for cancer imaging and safety study</td><td align="center" rowspan="2" colspan="1">Sun et al 2008</td></tr><tr><td align="center" rowspan="1" colspan="1">(NCT00379132, NCT00733798, NCT00040573)</td></tr><tr><td align="center" rowspan="1" colspan="1">Nucant pseudopeptide (N6L)</td><td align="center" rowspan="1" colspan="1">Binding nucleolin and nucleophosmin</td><td align="center" rowspan="1" colspan="1">Phase I/IIa, Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy on Advanced Solid Tumors (NCT01711398)</td><td align="center" rowspan="1" colspan="1">Latorre et al. 2014 (submitted) Destouches et al. 2011</td></tr><tr><td align="center" rowspan="1" colspan="1">Antibodies</td><td align="center" rowspan="1" colspan="1">Trastuzumab</td><td align="center" rowspan="1" colspan="1">Her2/neu receptor</td><td align="center" rowspan="1" colspan="1">Accepted by FDA and over the world (Herceptin as commercial formulation for breast cancer)</td><td align="center" rowspan="1" colspan="1">Hu et al. 2005</td></tr><tr><td align="center" rowspan="1" colspan="1">Aptamers</td><td align="center" rowspan="1" colspan="1">E10030</td><td align="center" rowspan="1" colspan="1">Anti-platelet-derived growth factor (anti PDGF-B)</td><td align="center" rowspan="1" colspan="1">Phase III for Age-Related Macular Degeneration (in complement with other anti-VEGF drug) NCT01940900</td><td align="center" rowspan="1" colspan="1">No research studies with IONPs</td></tr><tr><td align="center" rowspan="1" colspan="1">Folic Acid</td><td align="center" rowspan="1" colspan="1">Folate</td><td align="center" rowspan="1" colspan="1">Folate receptors</td><td align="center" rowspan="1" colspan="1">Several clinical studies of folic acid conjugated to anti-cancer drugs (NCT00485563, NCT00485563, NCT00291785, etc.)</td><td align="center" rowspan="1" colspan="1">Fan et al. 2011</td></tr></tbody></table></alternatives></table-wrap><fig id="fig3-58841" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Functionalization of IONPs Schematic representation to scale of IONPs and the structure of different molecules used for their functionalization Structures represented: IONPs doxorubicin RGD peptide (PDB ID: 3VI4) chlorotoxin (PDB ID: 1CHL) azurin p28 peptide (PDB ID: 4AZU) Nucant (N6L) [<xref rid="bibr52-58841" ref-type="bibr">52</xref>] aptamer (PDB ID 4HQU) and antibody (PDB ID: 1IGT).</p></caption><graphic xlink:href="10.5772_58841-fig3"/></fig><sec id="section7-58841"><title>3.1 Cell-penetrating peptides (CPPs)</title><p>Cell-penetrating peptides (CPPs), also known as protein transduction domains (PTDs) are up to 30-amino acid amphiphilic peptides that can be internalized by cells using mechanisms that require no energy and that can be receptor-mediated or not. Among the large variety of CPPs sequences, the presence of positively-charged amino acids and the amphiphilic character are the two common characteristics [<xref rid="bibr30-58841" ref-type="bibr">30</xref>]. First used for intracellular delivery of macromolecules [<xref rid="bibr31-58841" ref-type="bibr">31</xref>], CPPs are very interesting as drug and NPs intracellular delivery carriers. IONPs functionalized with different amounts of Tat peptide showed an exponential increase of cell uptake by increasing the number of CPPs grafted onto IONPs, concluding in a multivalent effect on the internalization [<xref rid="bibr32-58841" ref-type="bibr">32</xref>]. The important parameters for the entrance of CPPs are positive charge and amphiphilic character. Martin <italic>et al.</italic> [<xref rid="bibr33-58841" ref-type="bibr">33</xref>] and Cavalli <italic>et al.</italic> [<xref rid="bibr34-58841" ref-type="bibr">34</xref>] studied the use of guanidine-based dendritic structures and synthetic peptides mimicking CPPs' properties for IONP functionalization. Both studies, with different cell lines, had comparable results to the ones observed with CPPs. The interest in using synthetic structures is due to their stability toward protease degradation. These examples show that the conjugation of IONPs with CPPs and analogue peptides with similar physical properties can be used to improve the cellular uptake of IONPs.</p><p>Additionally, newly identified tumour-homing CPPs have been discovered, expanding the use of CPPs for selective tumour targeting [<xref rid="bibr35-58841" ref-type="bibr">35</xref>][<xref rid="bibr36-58841" ref-type="bibr">36</xref>]. The only cell-penetrating peptide that has been tested in clinical trials is the so-called p28 peptide, which is derived from azurin protein and induces an increase of p53 and consequently cell death by apoptosis [<xref rid="bibr37-58841" ref-type="bibr">37</xref>]. A completed phase I study (NCT00914914) and an ongoing phase I study (NCT01975116) have been carried out with the p28 peptide used as an anticancer drug for different types of tumours [<xref rid="bibr38-58841" ref-type="bibr">38</xref>]. As far as we know, this p28 peptide has never been tested for IONP functionalization or for targeting strategies.</p></sec><sec id="section8-58841"><title>3.2 Antibodies and other proteins</title><p>Antibodies are complex protein molecules that bind to specific antigens with high affinity. Antibodies can be developed to bind to almost any given antigen, for example, specific receptors expressed on the surface of cells, and are therefore very useful tools to target disease biomarkers. Apart from their use as anticancer agents [<xref rid="bibr39-58841" ref-type="bibr">39</xref>], antibodies have been used in IONP functionalization for their targeting properties toward cancer cells for a decade. As shown in the preliminary and encouraging study of Kang <italic>et al.</italic> in 2002 [<xref rid="bibr40-58841" ref-type="bibr">40</xref>], IONPs can be functionalized with an antibody against E-selectin, an adhesion molecule induced in cancer cells. The final nanostructure was able to bind HUVEC cells specifically when the overexpression of E-selectin is previously activated.</p><p>Numerous research groups are interested in the functionalization of IONPs with trastuzumab, a commercial and approved antibody for breast cancer treatment [<xref rid="bibr41-58841" ref-type="bibr">41</xref>], for the development of targeted therapeutic strategies. Most of the studies confirmed the selectivity of the antibody-functionalized IONPs toward cell lines overexpressing the Her2 receptor, depending on receptor expression level [<xref rid="bibr42-58841" ref-type="bibr">42</xref>][<xref rid="bibr43-58841" ref-type="bibr">43</xref>]. Vigor <italic>et al.</italic> showed similar results using another antibody that binds carcinoembryonic antigen (CEA), a receptor overexpressed in colorectal cancer cells [<xref rid="bibr44-58841" ref-type="bibr">44</xref>]. The use of antibodies for intracellular uptake of IONPs is currently developing and several works have examined the cell line specifically targeting the enhancement of the uptake.</p><p>Additionally, other proteins are being used to functionalize IONPs and improve the cellular uptake and cell targeting. The example of transferrin-functionalized IONPs to target cancer's overexpression of transferring receptors has been recently published by Piraux <italic>et al.</italic> in 2013 [<xref rid="bibr45-58841" ref-type="bibr">45</xref>].</p></sec><sec id="section9-58841"><title>3.3 Targeting peptides</title><p>Apart from macromolecules such as antibodies and CPPs, smaller peptides also interact with specific receptors in the cell membrane and increase the cellular uptake of the functionalized IONPs.</p><p>Arginine-glycine-aspartic acid, also known as RGD peptide, binds to the integrin receptor (&#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub>) which is overexpressed in several cancer cell lines and is commonly used as a targeting agent. Several works show that the functionalization of IONPs with RGD peptide (in linear or cyclic conformation) induces a significant increase in the cell uptake, compared to bare IONPs, specifically for &#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub> positive cell lines as in some cancer cell lines (BT-20 and HeLa) and no significant changes in &#x003b1;<sub>v</sub>&#x003b2;<sub>3</sub> negative cells (9L, MCF-7, or U87MG cells) [<xref rid="bibr46-58841" ref-type="bibr">46</xref>][<xref rid="bibr47-58841" ref-type="bibr">47</xref>][<xref rid="bibr48-58841" ref-type="bibr">48</xref>]. Similarly, chlorotoxin (CTX) is a 36-amino acid peptide that has a high selectivity and binding affinity for gliomas and neuroectodermal tumours [<xref rid="bibr49-58841" ref-type="bibr">49</xref>]. Sun <italic>et al.</italic> showed a tenfold increase in the cellular uptake of CTX-functionalized IONPs compared to bare IONPs in 9L cells [<xref rid="bibr50-58841" ref-type="bibr">50</xref>]. Nucant pseudopeptide (N6L) is a 4-kDa pseudopeptide currently in phase II clinical trials (NCT01711398), while the MultiFun European project (EU-FP7 no. 262943) is currently working on the multifunctionalization of IONPs with N6L and anticancer drugs. The significance of this pseudopeptide is that it acts as a targeting agent through its specific binding to nucleolin and nucleophosmin (overexpressed in several cancers) and also as a therapeutic agent [<xref rid="bibr51-58841" ref-type="bibr">51</xref>][<xref rid="bibr52-58841" ref-type="bibr">52</xref>]. The first results obtained showed the targeted uptake of N6L covalently-functionalized IONPs and the controlled release of N6L in a reducing medium which mimics the intracellular environment</p></sec><sec id="section10-58841"><title>3.4. Aptamers</title><p>Aptamers are single-stranded oligonucleotides that bind to their specific targets with high efficiency. Aptamers have been used for the targeting and specific cellular uptake of IONPs, as they present several advantages, such as their easy and reproducible synthesis, their good stability and their lack of immune response. Chen <italic>et al.</italic>, in 2011, developed PEG-IONPs functionalized with doxorubicin and sg8c aptamer. Sg8c binds to the cell membrane receptor protein tyrosine kinase 7 (PTK7). The study showed a clear specificity of sg8c-functionalized IONPs for PTK7 positive cells compared to PTK7 negative cells in correlation with the cytotoxicity of released doxorubicin under high pH of lysosome medium, which also showed a receptor-mediated entrance [<xref rid="bibr53-58841" ref-type="bibr">53</xref>].</p></sec><sec id="section11-58841"><title>3.5 Carbohydrates</title><p>Functionalization of IONPs with carbohydrates can improve cellular uptake by two different strategies: (1) providing higher hydrophilicity and biocompatibility and thus increasing lifetime in the bloodstream; and (2) the interaction with specific sugar receptors on the membrane of certain cell lines, including cancer cells [<xref rid="bibr54-58841" ref-type="bibr">54</xref>]. Moros <italic>et al</italic>. studied the uptake of IONPs functionalized with monosaccharides (glucose or galactose) compared to IONPs functionalized with PEG and showed that the type of carbohydrate affects the rate and the mechanism of internalization [<xref rid="bibr55-58841" ref-type="bibr">55</xref>]. In 2011, Valero <italic>et al</italic>. also showed interesting results using IONPs encapsulated within apoferritin (apomaghemite) and then functionalized with two carbohydrates, N-acetyl-D-glucosamine and D-mannose. First, they found similar behaviour to an MRI contrast agent such as the commercial agent Endorem. Finally, they also observed that both carbohydrate-functionalized apomaghemite NPs retained the carbohydrate lectin recognition activity [<xref rid="bibr56-58841" ref-type="bibr">56</xref>].</p></sec><sec id="section12-58841"><title>3.6 Folic acid</title><p>Folic acid, also known as Vitamin B9, is a natural product with an important role in DNA and RNA synthesis. Over 20 years, folate receptors have been shown to be overexpressed on several cancer cell lines and can therefore be used for targeting cancer cells and activated macrophages [<xref rid="bibr57-58841" ref-type="bibr">57</xref>][<xref rid="bibr58-58841" ref-type="bibr">58</xref>]. Folic acid has already been approved for several clinical applications. Clinical trials are in progress for drug-folate conjugate use in cancer diagnosis (NCT00003763) and therapy (NCT00291785, NCT00485563, NCT00441870). Folic acid has been widely used for 15 years in the development of NP targeting strategies for biomedical applications, including IONPs. We highlight the work of Fan <italic>et al.</italic> in 2011, where a significant enhancement of cellular uptake of the folic acid-functionalized IONPs is achieved compared to bare IONPs, depending on the receptor expression levels of the cell lines used. Promising results of MRI <italic>in vivo</italic> highlight the potential of folic acid-functionalized IONPs for clinical applications [<xref rid="bibr59-58841" ref-type="bibr">59</xref>].</p></sec><sec id="section13-58841"><title>3.7 Drugs</title><p>The functionalization of IONPs with drugs for their application as nanocarriers is a wide and much studied topic [<xref rid="bibr60-58841" ref-type="bibr">60</xref>]. Indeed, the major portion of the drugs used in combination with IONPs at the research level are already available in clinics, such as doxorubicin, gemcitabine and SN38, and are also involved in several clinical trials of drug-targeting agent conjugates. Currently, there are some promising examples of doxorubicin conjugated with antibodies now in clinical trials (NCT00051584), and the use of liposomal formulations for drug delivery (NCT01227941).</p><p>The multifunctionalization of IONPs by targeting agents and drugs, and its acceptance in clinical processes, might be a breakthrough in the development of specific therapies. The presence of targeting moieties such as those discussed above will increase the localization of IONPs in the diseased tissue, therefore augmenting drug delivery and local drug concentration. Thus, research is currently making efforts towards the multifunctionalization of IONPs. Different methodologies need to be developed to ensure controlled multifunctionalization, and preserve the stability and biological activities of active molecules attached to the particles. Additionally, with respect to the clinical application of these nanostructures, functionalization efforts are required to increase the blood half-life of the IONPs, minimizing off-target accumulation and immunological response.</p></sec></sec><sec id="section14-58841"><title>4. Toxicological profiles and potential interference with biological functions of cells</title><p>The above-mentioned parameters have a tremendous influence on cell internalization as well as <italic>in vivo</italic> behaviour, and hence in the administration procedure of choice for clinical applications [<xref rid="bibr61-58841" ref-type="bibr">61</xref>]. Mammalian cells internalize IONPs mainly through endocytosis mechanisms. However, the specific pathway depends on the cell type and physicochemical features of the IONPs. Most cells use different molecular pathways of pinocytosis, whereas cells from the reticuloendothelial system (RES) preferentially internalize IONPs by phagocytosis in a process that begins with the opsonization of the NPs in the bloodstream, followed by binding of the opsonized NPs to the cell surface and final ingestion [<xref rid="bibr62-58841" ref-type="bibr">62</xref>] (<xref ref-type="fig" rid="fig4-58841">Figure 4A</xref>). The IONPs approved for clinical use are not functionalized, but they display a variety of sizes that influence their administration and distribution within the body. SPIONs and USPION accumulate in the lungs, liver, spleen, lymph nodes, bone marrow vessels and capillaries, while VSPIONs also accumulate in the kidneys (<xref ref-type="fig" rid="fig4-58841">Figure 4B</xref>). Once in the body, the iron of the NP core is stored in the red blood cells and, like the endogenous iron, it is progressively eliminated via faeces, while the coating (mostly dextran-derived compounds) degrades and is eliminated by the kidneys. However, the IONPs interact with different biological systems in the body and may have adverse effects. Evaluating the toxicological effects of IONPs both <italic>in vitro</italic> and <italic>in vivo</italic> is crucial for the development of IONP-derived applications in medicine.</p><fig id="fig4-58841" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>A. Different internalization pathways of IONPs in mammalian cells. Possible mechanisms of uptake including macropinocytosis, caveolae- and clathrin-mediated endocytosis, phagocytosis, passive diffusion and other endocytosis pathways. After internalization, IONPs can produce cytotoxicity effects via a Fenton reaction. Hydroxyl radicals generated could damage DNA, proteins or lipids (8-OH-dG = 8 hydroxydeoxyguanosine, MDA = malondialdehyde, HNE = 4-hydroxy-2-nonenal), triggering genotoxicity. B. IONP administration in the human body, such as intrathecal, intratumoural, intravenous and intramuscular or subcutaneous methods.</p></caption><graphic xlink:href="10.5772_58841-fig4"/></fig><sec id="section15-58841"><title>4.1 Effects on cellular physiology</title><sec id="section16-58841"><title>4.1.1 Mitochondrial stress</title><p>One factor that can contribute to nanotoxicity is the size of the NPs. Smaller NPs have a greater reactive surface area than larger ones, are more chemically reactive, and produce greater numbers of reactive oxygen species (ROS) that include free radicals [<xref rid="bibr63-58841" ref-type="bibr">63</xref>]. SPIONs also can induce (geno-)toxicity via generation of ROS. SPIONs are presumably degraded into iron ions within the lysosomes by hydrolysing enzymes effective at low pH [<xref rid="bibr64-58841" ref-type="bibr">64</xref>]. This &#x0201c;free iron&#x0201d; can potentially cross the nuclear or mitochondrial membrane and, in the latter case, the free iron in the form of ferrous ions (Fe<sup>2+</sup>) can react with hydrogen peroxide and oxygen produced by the mitochondria to produce highly reactive hydroxyl radicals and ferric ions (Fe<sup>3+</sup>) via the Fenton reaction (<xref ref-type="fig" rid="fig3-58841">Figure 3a</xref>). Therefore, hydroxyl radicals generated by the free iron could damage DNA, proteins, polysaccharides and lipids <italic>in vivo</italic> [<xref rid="bibr65-58841" ref-type="bibr">65</xref>]. The cytotoxicity was also found to be dependent on various factors, such as type of surface coating or its breakdown products, chemical composition of cell medium, oxidation state of iron in SPION and protein&#x02013;SPION interaction [<xref rid="bibr24-58841" ref-type="bibr">24</xref>][<xref rid="bibr66-58841" ref-type="bibr">66</xref>][<xref rid="bibr67-58841" ref-type="bibr">67</xref>]. For example in IONPs, magnetite (Fe<sub>3</sub>O<sub>4</sub>) and maghaemite (Fe<sub>2</sub>O<sub>3</sub>) can show different cellular responses because of their ability to undergo oxidation/reduction reactions. In fact, magnetite has been shown to cause higher levels of oxidative DNA lesions in the A549 human lung epithelial cell line in the absence of decreased cell viability as compared to maghaemite, owing to its potential to undergo oxidation. It is hypothesized that the toxicity can, however, be decreased by coating magnetite NPs, resulting in fewer oxidative sites that are less reactive, thereby producing less DNA damage [<xref rid="bibr66-58841" ref-type="bibr">66</xref>].</p></sec><sec id="section17-58841"><title>4.1.2 Effects on actin cytoskeleton architecture</title><p>Intracellular accumulation of NPs can have profound effects on cell morphology. High levels of internalized particles can provoke cellular stress, inducing changes in the architecture of the actin cytoskeleton. An altered actin network displaying actin stress fibres can lead to a reduced proliferative capacity and cell spreading. It can also influence the migration and differentiation of stem cells.</p><p>In the case of IONPs, it has been reported to interfere with actin and tubulin structures, inducing cell retraction, rounding and deposition of massive dense filament matters adjacent to the nucleus and vacuoles in the cytoplasm [<xref rid="bibr68-58841" ref-type="bibr">68</xref>].</p></sec></sec><sec id="section18-58841"><title>4.2 Factors that can contribute to non-toxicity</title><p>Size is clearly a key factor in determining the potential toxicity of a particle. However, it is not the only important factor. Other properties of nanomaterials that influence toxicity include chemical composition, shape, surface structure, surface charge, aggregation and solubility [<xref rid="bibr63-58841" ref-type="bibr">63</xref>]. A study investigating the effect of different surface coatings on cell behaviour and morphology has shown that dextranmagnetite (Fe<sub>3</sub>O<sub>4</sub>) NPs result in cell death and reduced proliferation similar to that caused by uncoated IONPs [<xref rid="bibr24-58841" ref-type="bibr">24</xref>]. Other authors have reported the formation of gas vesicles after exposure to the uncoated NPs, resulting in altered protein functions and changes in ionic equilibrium within the cells, which also promotes toxicity [<xref rid="bibr69-58841" ref-type="bibr">69</xref>].</p></sec><sec id="section19-58841"><title>4.3 In vitro and in vivo toxicity of nanoparticles in 2D vs. 3D cell culture</title><p>Common 2D cell cultures do not adequately represent the functions of 3D tissues that have extensive cell&#x02013;cell and cell&#x02013;matrix interactions, as well as markedly different diffusion/transport conditions. Hence, testing cytotoxicity in 2D cultures may not accurately reflect the actual toxicity of NPs and other nanostructures in the body [<xref rid="bibr70-58841" ref-type="bibr">70</xref>]. For instance, recent studies on toxicity testing of magnetic NPs, using <italic>in vitro</italic> 2D cell culture, demonstrated high cytotoxic effects. However, when they were tested in animal models, no adverse effects were observed [<xref rid="bibr71-58841" ref-type="bibr">71</xref>]. Therefore, <italic>in vitro</italic> 3D cell culture models have been introduced to bridge the gap between <italic>in vitro</italic> 2D cell culture and <italic>in vivo</italic> models. Some authors report that bare IONPs were more toxic at lower concentrations in 3D culture, compared with 2D culture cells. This may be due to the increased contact area between NPs and cells in 3D culture [<xref rid="bibr72-58841" ref-type="bibr">72</xref>].</p><p>When IONPs enter the body, absorption can occur through interaction with biological components such as proteins and cells; afterwards, they can distribute into various organs where they may remain in the same nanostructure or become metabolized [<xref rid="bibr73-58841" ref-type="bibr">73</xref>]. A systematic and thorough quantitative analysis of the pharmacokinetics (i.e., absorption, distribution, metabolism and excretion) of IONPs can lead to improvements in design of biocompatible IONPs, a better understanding of NPs' non-specificity toward tissues and cell types, and assessments of basic distribution and clearance that serve as the basis to understand their activity and potential toxicity [<xref rid="bibr74-58841" ref-type="bibr">74</xref>].</p><p>The surface of IONPs is rapidly covered by selective sets of blood plasma proteins after injection. Small IONPs (&#x0003c; 10 nm) are usually rapidly removed through extravasation and renal clearance, whereas large IONPs (&#x0003e; 200 nm) are sequestered by the spleen via mechanical filtration [<xref rid="bibr75-58841" ref-type="bibr">75</xref>]. The typical final biodistribution of IONPs is 80&#x02013;90 in liver, 5&#x02013;8% in spleen and 1&#x02013;2% in bone marrow, due to the high number of macrophages contained in these organs [<xref rid="bibr61-58841" ref-type="bibr">61</xref>]. IONPs were also found to be distributed in the brain, liver, spleen and lungs after their inhalation, demonstrating their ability to cross the blood&#x02013;brain barrier [<xref rid="bibr76-58841" ref-type="bibr">76</xref>] (<xref ref-type="fig" rid="fig4-58841">Figure 4A</xref>).</p></sec></sec><sec id="section20-58841"><title>5. Current clinical applications</title><p>In December 1996, the United States Food and Drug Administration (FDA) approved GastroMARK (AMAG Pharmaceuticals), an aqueous suspension of silicone coated, superparamagnetic iron oxide NPs, intended for oral administration, as a magnetic resonance (MR) imaging contrast medium to enhance the delineation of the bowel to distinguish it from organs and tissues that are adjacent to it in the upper regions of the gastrointestinal tract (<ext-link ext-link-type="uri" xlink:href="http://www.fda.gov">www.fda.gov</ext-link>). The approval of GastroMARK, together with a number of preclinical studies supporting the potential use of SPIONs in different medical applications, contributed significantly to expanding clinical research in nanomedicine. A number of new SPION-derived products were developed, some of which were also approved by the FDA and the European Commission (EC) for clinical use. Additionally, the increasing number of clinical trials using these new NPs expanded their potential medical applications. Sixteen years later, just two SPION-derived products are approved by the FDA and commercially available: GastroMARK and ferumoxytol (<xref rid="table3-58841" ref-type="table">Table 3</xref>). In the following paragraphs, we will describe the current clinical applications of SPION-derived products, as well as the clinical trials testing them for promising applications such as cell tracking and hyperthermia.</p><table-wrap id="table3-58841" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Iron oxide nanoparticles (ION) for clinical applications: the table displays the chronology of ION approved by the Food and Drug Administration (FDA) and/or the European Commission (EC), discontinued and/or production abandoned. Sinerem's Authorization Application was withdrawn by Guerbet (European partner of AMAG Pharma) in 2007. Ferumoxide was discontinued by AMAG Pharma in 2008 and the production of Retrovist was abandoned in 2009.</p></caption><alternatives><graphic xlink:href="10.5772_58841-table3"/><table frame="border" rules="all" width="100%"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Date</th><th align="center" rowspan="1" colspan="1">Events</th><th align="right" rowspan="1" colspan="1">Indication</th><th align="center" rowspan="1" colspan="1">Size</th><th align="center" rowspan="1" colspan="1">Adm.</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">1996</td><td align="left" rowspan="1" colspan="1">Lumirem (Gastromark (US)): approved by FDA</td><td align="left" rowspan="1" colspan="1">Contrast agent for MRI for the gastrointestinal tract</td><td align="center" rowspan="1" colspan="1">50 nm</td><td align="center" rowspan="1" colspan="1">Oral</td></tr><tr><td align="center" rowspan="1" colspan="1">1996</td><td align="left" rowspan="1" colspan="1">Ferumoxides (Emdorem (EU) or Feridex 1.V.): approved by the FDA</td><td align="left" rowspan="1" colspan="1">Contrast agent for MRI of liver lesions</td><td align="center" rowspan="1" colspan="1">120&#x02013;180 nm</td><td align="center" rowspan="1" colspan="1">Injectable solution</td></tr><tr><td align="center" rowspan="1" colspan="1">2001</td><td align="left" rowspan="1" colspan="1">Ferucarbotran (Resovist or (Cliavist(EU)): approved for Europena Market</td><td align="left" rowspan="1" colspan="1">Contrast-enhanced MRI of the liver</td><td align="center" rowspan="1" colspan="1">45&#x02013;60 nm</td><td align="center" rowspan="1" colspan="1">Injectable solution</td></tr><tr><td align="center" rowspan="1" colspan="1">2005</td><td align="left" rowspan="1" colspan="1">Ferumoxtram (Sinerem (EU) or (Combidex (US)): AMAG Pharma received an approvable letter from the FDA</td><td align="left" rowspan="1" colspan="1">Detection and characterization of metastatic lymph nodes in patients with pelvic cancer</td><td align="center" rowspan="1" colspan="1">10&#x02013;40 nm</td><td align="center" rowspan="1" colspan="1">Injectable solution</td></tr><tr><td align="center" rowspan="1" colspan="1">2006</td><td align="left" rowspan="1" colspan="1">Sinerem: submitted European Marketing Authorization Application</td><td align="left" rowspan="1" colspan="1">Detection and characterization of metastatic lymph nodes in patients with pelvic cancer</td><td align="center" rowspan="1" colspan="1">10&#x02013;40 nm</td><td align="center" rowspan="1" colspan="1">Injectable solution</td></tr><tr><td align="center" rowspan="1" colspan="1">2009</td><td align="left" rowspan="1" colspan="1">Feraheme (Ferumoxytol): approbed by the FDA</td><td align="left" rowspan="1" colspan="1">Iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease.</td><td align="center" rowspan="1" colspan="1">20&#x02013;50 nm</td><td align="center" rowspan="1" colspan="1">intravenous</td></tr><tr><td align="center" rowspan="1" colspan="1">2012</td><td align="left" rowspan="1" colspan="1">Feraheme (Ferumoxytol): approbed by the EC</td><td align="left" rowspan="1" colspan="1">Iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease.</td><td align="center" rowspan="1" colspan="1">20&#x02013;50 nm</td><td align="center" rowspan="1" colspan="1">intravenous</td></tr></tbody></table></alternatives></table-wrap><sec id="section21-58841"><title>5.1 Imaging</title><p>Clinic imaging technologies rely on the use in MRI, optical imaging/MRI and MRI/PEP. SPIONs function as a negative contrast agent, decreasing T2 signals and thus the signal intensity. They cause a magnetic field gradient that affects the surrounding protons of water molecules, disrupting the homogeneity of the magnetic field, which can be observed by MRI [<xref rid="bibr77-58841" ref-type="bibr">77</xref>]. Additionally, SPIONs display lymphotropic properties, as phagocytes of the RES internalize them, causing local changes in magnetic properties. These features make the SPIONs an excellent alternative to complement current contrast agents in MRI, providing higher accuracy in some conditions such as autoimmune diseases, cardiovascular and cerebrovascular pathologies, and cancer (<xref rid="table4-58841" ref-type="table">Table 4</xref>). Additionally, the low toxicity both <italic>in vitro</italic> and <italic>in vivo</italic>, and their feasibility in enhancing the contrast of cellular targets in MRI, make then suitable for <italic>in vivo</italic> tracking of transplanted cells (<xref ref-type="fig" rid="fig5-58841">Figure 5</xref>) [<xref rid="bibr78-58841" ref-type="bibr">78</xref>].</p><table-wrap id="table4-58841" orientation="portrait" position="float"><label>Table 4.</label><caption><p><ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> search with the number of results and reference ID. Search terms: Superparamagnetic OR Iron Oxide OR SPIO OR USPIO OR VSPIO.</p></caption><alternatives><graphic xlink:href="10.5772_58841-table4"/><table frame="border" rules="all" width="100%"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"><ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link></th><th align="center" colspan="5" rowspan="1">Imaging</th><th align="center" colspan="3" rowspan="1">Therapy</th></tr><tr><th align="center" rowspan="1" colspan="1">Indication</th><th align="center" rowspan="1" colspan="1">Lymph nodes</th><th align="center" rowspan="1" colspan="1">Head and neck cancer</th><th align="center" rowspan="1" colspan="1">Cardiovascular and Cerebrovascular diseases</th><th align="center" rowspan="1" colspan="1">Autoimmune diseases</th><th align="center" rowspan="1" colspan="1">Cell tracking</th><th align="center" rowspan="1" colspan="1">Delivery</th><th align="center" rowspan="1" colspan="1">Anemia</th><th align="center" rowspan="1" colspan="1">Hyperthermia</th></tr></thead><tbody valign="top"><tr><td align="center" rowspan="1" colspan="1"><bold>April 2014 (53)</bold><break/><break/><break/><break/><break/><break/><break/><break/><bold>Clinical Trial Identificator</bold></td><td align="center" rowspan="1" colspan="1">10<break/><break/>NCT01815333<break/>NTC00147238<break/>NTC00920023<break/>NCT01927887<break/>NCT00188695<break/>NCT00147238<break/>NCT01296139<break/>NCT00243594<break/>NCT00416455<break/>NCT00107484</td><td align="center" rowspan="1" colspan="1">7<break/><break/><break/>NCT01895829<break/>NCT0660543<break/>NCT00769093<break/>NCT01663090<break/>NCT00978562<break/>NCT00659126<break/>NCT00659334</td><td align="center" rowspan="1" colspan="1">7<break/><break/><break/>NCT01127113<break/>NCT01323296<break/>NCT01995799<break/>NCT01674257<break/>NCT01749280<break/>NCT00794092<break/>NCT02084303</td><td align="center" rowspan="1" colspan="1">4<break/><break/><break/><break/><break/>NCT01973517<break/>NCT00585936<break/>NCT02006108<break/>NCT01243320</td><td align="center" rowspan="1" colspan="1">6<break/><break/><break/><break/>NCT00972946<break/>NCT01169935<break/>NCT01127113<break/>NCT00660543<break/>NCT00243594<break/>NCT00781872</td><td align="center" rowspan="1" colspan="1">3<break/><break/><break/><break/><break/>NCT01270139<break/>NCT01436123<break/>NCT01927887</td><td align="center" rowspan="1" colspan="1">14<break/>NCT01052779<break/>NCT01114217<break/>NCT01114139<break/>NCT00114204<break/>NCT01374919<break/>NCT01264679<break/>NCT01227616<break/>NCT01155388<break/>NCT01942460<break/>NCT00233597<break/>NCT00255437<break/>NCT01148745<break/>NCT00255450<break/>NCT01950247</td><td align="center" rowspan="1" colspan="1">2<break/><break/><break/><break/><break/><break/><break/>NCT02033447<break/>DRKS00005476</td></tr></tbody></table></alternatives></table-wrap><fig id="fig5-58841" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>Organ distribution of systemically injected nanoparticles. a. Common organ distribution is shown as a function of particle size. b. Example of the <sup>99m</sup>Tc-labeled graft copolymer used in a human patient and <sup>89</sup>Zr-labeled cross-linked dextran nanoparticles used in a mouse model. This figure was reproduced with permission from <italic>Nature Materials</italic> [<xref rid="bibr126-58841" ref-type="bibr">126</xref>].</p></caption><graphic xlink:href="10.5772_58841-fig5"/></fig><sec id="section22-58841"><title>5.1.1 Diagnostic tools</title><sec id="section23-58841"><title>5.1.1.1 Diagnosis in immunological diseases</title><p>Autoimmune disease and inflammation processes are characterized by the activation of the endothelium that eventually allows for the extravasation of macrophages from the bloodstream into the inflamed tissue. SPIONs significantly enhance the signal of these events when analysed by MRI, as they are quickly captured by macrophages. In the last few years, a number of authors have taken advantage of this observation and carried out different clinical assays to test the value of SPIONs as a negative contrast in a variety of autoimmune and inflammatory conditions. Oral USPION (ferumoxytol) improved the detection of Crohn's disease [<xref rid="bibr79-58841" ref-type="bibr">79</xref>] and the prognosis of active ulcerative colitis [<xref rid="bibr80-58841" ref-type="bibr">80</xref>][<xref rid="bibr81-58841" ref-type="bibr">81</xref>]. Using ferumoxtran, a significant improvement was observed in a small cohort of Type 1A diabetes patients (NCT00585936) in the diagnosis of pancreatic islet inflammation when compared to T1-gadolinium [<xref rid="bibr82-58841" ref-type="bibr">82</xref>]. In patients with multiple sclerosis, USPION-based MRI showed that iron oxide NPs labelled larger and better defined areas, allowing the detection of what has been referred to as normal-appearing white matter that is histologically affected (NCT01973517) [<xref rid="bibr83-58841" ref-type="bibr">83</xref>][<xref rid="bibr84-58841" ref-type="bibr">84</xref>]. These outstanding results have encouraged physicians and researchers to continue testing the SPION-based MRI in both the previous and new immunological and inflammatory conditions. At least two more clinical trials were running at the time of writing this review (<xref rid="table4-58841" ref-type="table">Table 4</xref>).</p></sec><sec id="section24-58841"><title>5.1.1.2 Diagnosis in cardiovascular and cerebrovascular pathologies</title><p>The use of SPIONs for T2 and T2-weighted cardiovascular magnetic resonance imaging (CMR) has been successfully validated to detect myocardial oedema and myocardial haemorrhage [<xref rid="bibr85-58841" ref-type="bibr">85</xref>][<xref rid="bibr86-58841" ref-type="bibr">86</xref>]. In a more recent trial, Vilmaz <italic>et al</italic>. demonstrated that ferumoxytol significantly improved the signal in the myocardial infarction area when compared with gadolinium-based contrast images. This improvement was due to the accumulation of USPIONs in infiltrating macrophages [<xref rid="bibr87-58841" ref-type="bibr">87</xref>]. Similarly, Sigovan <italic>et al</italic>. demonstrated that ferumoxytol-enhanced MR angiography rendered superior image quality compared with non-enhanced time-of-flight MR when studying upper extremity autogenous fistulas in patients with renal failure. The use of ferumoxytol reduced flow artefacts while simultaneously raising lumen depiction scores, thus obtaining a more homogeneous luminal signal enhancement [<xref rid="bibr88-58841" ref-type="bibr">88</xref>]. The ability to detect macrophage activity of plaque inflammation by MRI has also supported the use of SPION-based MRI of carotid atherosclerosis to predict cerebrovascular and cardiovascular morbidity and mortality. The author found an interesting association between USPIO-defined plaque inflammation and the development of vascular events, although the association was not significant due, in part, to the relatively low baseline risk of vascular event of the patient included in the clinical trial [<xref rid="bibr89-58841" ref-type="bibr">89</xref>]. However, the overall data available from different trials aim to leverage the SPION-based MRI to assess the diagnosis of cardiovascular and cerebrovascular pathology in the next year. Thus it will be very important to pay special attention to the results derived from the ongoing clinical trials (<xref rid="table4-58841" ref-type="table">Table 4</xref>).</p></sec><sec id="section25-58841"><title>5.1.1.3 Diagnosis in cancer</title><p>In healthy liver, spleen and lymph node tissue, IONPs decrease the MR signal intensity as phagocytic cells uptake the nanoparticles, while malignant tissue generally fails to uptake IONPs and appears bright relative to the surrounding tissue [<xref rid="bibr90-58841" ref-type="bibr">90</xref>][<xref rid="bibr91-58841" ref-type="bibr">91</xref>]. This observation emphasizes the IONP-enhanced MRI as an extremely promising imaging technique for the preoperative detection of metastatic disease in lymph nodes. In 2003, Harisinghani <italic>et al</italic>. reported that high-resolution MRI with IONPs (Sinerem) allowed the detection of small and otherwise undetectable lymph-node metastases in patients with prostate cancer, demonstrating the sensitivity and specificity of the technique [<xref rid="bibr92-58841" ref-type="bibr">92</xref>]. From this point of departure, a number of clinical trials have successfully tested the IONP-enhanced MRI to detect sentinel lymph nodes in prostate cancer [<xref rid="bibr93-58841" ref-type="bibr">93</xref>][<xref rid="bibr94-58841" ref-type="bibr">94</xref>], as well as other types of cancers like bladder [<xref rid="bibr95-58841" ref-type="bibr">95</xref>], breast (Endorem [<xref rid="bibr96-58841" ref-type="bibr">96</xref>] and Resovist [<xref rid="bibr97-58841" ref-type="bibr">97</xref>][<xref rid="bibr98-58841" ref-type="bibr">98</xref>]) and renal cell (Sinerem) [<xref rid="bibr99-58841" ref-type="bibr">99</xref>], among others (<xref rid="table4-58841" ref-type="table">Table 4</xref>).</p></sec></sec><sec id="section26-58841"><title>5.1.2 Cell tracking in cell transplantation-mediated therapies</title><p>Cell therapy relies on the delivery of cells to the target site. Monitoring and tracking these cells to ensure tissue delivery and engraftment become a key issue in stabilizing clinical safety and therapeutic efficacy. In this sense, detection by MRI of IONP-labelled cells may be one of the most promising approaches for a short-term evaluation [<xref rid="bibr100-58841" ref-type="bibr">100</xref>]. Although the FDA and EC have not yet approved their use for <italic>in vivo</italic> cell tracking, a few clinical trials have evaluated their feasibility and safety in different contexts (NCT00972946, NCT01169935 and NCT01127113). To evaluate the feasibility, safety and immunological effects of intrathecal and intravenous administration of autologous mesenchymal stem cells in patients with multiple sclerosis (MS) and amyotrophic lateral sclerosis, Karussis <italic>et al</italic>. designed and carried out a clinical trial in which MSC were magnetically labelled with ferumoxides. The MSC were incubated with ferumoxides in the presence of poly-L-lysine for 24 to 48 hours prior to transplantation. MRI examination of the brain and spinal cord was performed at 24 and 48 hours, and later at one to three months. The image revealed a possible migration of such cells to the meninges of the spinal cord and nerve roots, and to the spinal cord parenchyma, although they could not rule out the possibility that macrophages had phagocytized the iron oxide magnetic NPs and migrated to the inflammatory MS lesions [<xref rid="bibr101-58841" ref-type="bibr">101</xref>]. In a different work, Richards <italic>et al</italic>. successfully SPION-labelled human peripheral blood mononuclear cells (PBMC) and performed intramuscular and intravenous administration of labelled cells in healthy volunteers without remarkable side effects. After administration of labelled cells, the signal intensity was reduced in the liver and spleen, reflecting dose-dependent accumulation of SPION-labelled cells. This work demonstrated that labelled cells can be visualized <italic>in vivo</italic> at clinically relevant field strengths after local or systemic administration, and that SPION-labelled cells can be tracked to a site of focal inflammation in humans. More importantly, however, they demonstrated that intravenous administration of SPION-labelled cells in humans is safe [<xref rid="bibr78-58841" ref-type="bibr">78</xref>].</p><p>Cancer immunotherapy approaches can also benefit from SPION labelling technology. Dendritic cell (DC) vaccines have been used to induce tumour-specific cytotoxic T cells. To be successful, injected DCs need to migrate to the lymph nodes (LNs) where they can stimulate effector T cells. DCs have previously been labelled with radionuclides for scintigraphic imaging, which is the only clinical cellular imaging modality approved by the FDA [<xref rid="bibr102-58841" ref-type="bibr">102</xref>][<xref rid="bibr103-58841" ref-type="bibr">103</xref>]. deVris <italic>et al</italic>. investigated the biodistribution of SPION-labelled DCs applied as cancer vaccines in melanoma patients using MRI, and demonstrated that MRI allowed assessment of the accuracy of DC delivery and of inter- and intranodal cell migration patterns [<xref rid="bibr104-58841" ref-type="bibr">104</xref>].</p></sec></sec><sec id="section27-58841"><title>5.2 Therapy</title><sec id="section28-58841"><title>5.2.1 Delivery</title><p>Iron oxide NPs have been successfully used as a carrier for bioactive molecules in a number of conditions both <italic>in vitro</italic> and in animal models [<xref rid="bibr105-58841" ref-type="bibr">105</xref>]. In the last few years, SPIONs have also been demonstrated to be useful in clinical settings (NCT01270139, NCT01436123 and NCT01927887). In 2009 Provenzano <italic>et al</italic>. reported that rapid intravenous injection of ferumoxytol led to significantly greater haemoglobin increases compared with oral iron, and was also well tolerated in all patients [<xref rid="bibr106-58841" ref-type="bibr">106</xref>]. The same year, ferumoxytol was approved by the FDA, and later in 2012 by the EC, as an iron replacement therapy indicated for the treatment of iron deficiency anaemia in adult patients with chronic kidney disease. Since then, a number of clinical trials have extended the use of ferumoxytol as intravenous iron delivery/therapy to other iron deficiency conditions. Ferumoxytol was effective and well tolerated in adult patients with iron deficiency anaemia in whom oral iron was ineffective or could not be used [<xref rid="bibr107-58841" ref-type="bibr">107</xref>][<xref rid="bibr108-58841" ref-type="bibr">108</xref>], and showed comparable efficacy and adverse event rates to the first choice, iron sucrose [<xref rid="bibr109-58841" ref-type="bibr">109</xref>], even in paediatric patients [<xref rid="bibr110-58841" ref-type="bibr">110</xref>].</p></sec><sec id="section29-58841"><title>5.2.2 Hyperthermia</title><p>Thermotherapy of solid tumours is one of the most promising applications of SPIONs, either alone or in combination with adjuvant treatments, such as chemotherapy or radiation. The principle of applying IONPs to hyperthermia therapy involves the administration of an IONPs fluid within the tumour, followed by the application of an alternating magnetic field. These nanoparticles achieve high temperatures, promoting warming of the region. Temperature elevation in the range of 41&#x02013;46 <underline>&#x000b0;</underline>C can induce several effects at both cellular and tissue levels [<xref rid="bibr111-58841" ref-type="bibr">111</xref>]. Cellular hyperthermia induces heat stress, resulting in high level of heat-shock protein expression, protein denaturation and folding and apoptosis. At the tissue level, temperature elevation induces changes in pH, perfusion and oxygenation of the tumour microenvironment [<xref rid="bibr112-58841" ref-type="bibr">112</xref>][<xref rid="bibr113-58841" ref-type="bibr">113</xref>], while higher temperature (hyperthermia) or longer treatment time may lead to necrosis.</p><p>Clinical studies for the application of thermotherapy using IONPs in humans were initiated in 2007 on prostate cancer and glioblastoma patients (NCT02033447 and DRKS00005476). Johannsen <italic>et al</italic>. injected the IONPs fluid transperineally into the prostate of ten patients who received six thermal therapies of 60 minutes duration at weekly intervals. They reached maximum temperatures of 55 <underline>&#x000b0;</underline>C in the prostate with a median temperature of 40.7 <underline>&#x000b0;</underline>C within the tumour and 40.2 <underline>&#x000b0;</underline>C in peritumoural zones. With this assay they demonstrated the feasibility of thermotherapy [<xref rid="bibr114-58841" ref-type="bibr">114</xref>]. Afterwards, they carried out a different clinical assay demonstrating that interstitial heating using IONPs was feasible and well tolerated in patients with locally recurrent prostate cancer, and the deposition of nanoparticles in the prostate was highly durable [<xref rid="bibr52-58841" ref-type="bibr">52</xref>].</p><p>In parallel, Maier-Hauff <italic>et al</italic>. evaluated the feasibility and tolerability of thermotherapy in patients with recurrent glioblastoma multiforme. In this trial, patients received four to 10 thermotherapy treatments, reaching a median intratumoural temperature of 44.6 <underline>&#x000b0;</underline>C. The authors observed that thermotherapy using IONPs was tolerated well by all patients with minor or no side effects [<xref rid="bibr115-58841" ref-type="bibr">115</xref>]. A few years later, they carried out another clinical trial and observed that the median overall survival following diagnosis of first tumour recurrence was 13.4 months, which was an improvement compared to the 6.2 months in other reference studies in the field. Additionally, the median of overall survival after primary tumour diagnosis was 23.2 months, compared with just 14.6 in the reference groups [<xref rid="bibr116-58841" ref-type="bibr">116</xref>].</p><p>More recently, Matsumine <italic>et al</italic>. reported the utilization of hyperthermia in patients with metastatic bone tumours. The authors carried out an initial surgical intervention followed by the implantation of a mixture of &#x0201c;bare&#x0201d; magnetite NPs and calcium phosphate cement, which is a biocompatible bone substitute. The patients were treated for 15 minutes every two days starting from the eighth day after surgery. Thirty-two percent of lesions were reduced and presented visible bone formation, 64% showed no progressive lesions for more than three months and just 4% presented a poor response to the treatment, demonstrating safety and effectiveness [<xref rid="bibr117-58841" ref-type="bibr">117</xref>].</p><p>Although these results are promising, the development of therapies based on magnetic hyperthermia is still in its very early stages. In the next few years, many biological and technical advances need to be achieved before this new therapy becomes part of the standard of care for some cancers. Questions such as how to reach homogenous distribution of IONPs and therapeutic temperature, and how to minimize peritumoural tissue damage, need to be addressed. In this regard, a new phase 0 clinical trial to investigate the magnetic nanoparticle thermo-ablation-retention and maintenance in the prostate is being performed by the University College London Hospitals (NCT 02033447). In this trial, the authors will test whether the magnetic nanoparticles actually stay where they are injected or move to sensitive structures around the prostate, which may lead to undesirable side effects. Finally, MagForce is conducting a new open-label, randomized clinical trial employing magnetic hyperthermia to treat glioblastoma multiforme patients (DRKS00005476). The purpose of this trial, expected to enrol up to 285 patients, is to test the feasibility and safety of using magnetic hyperthermia as a stand-alone therapy and in combination with radiotherapy using the commercial IONPs NanoTherm&#x000ae;. The results will help magnetic hyperthermia advance in the clinical setting.</p></sec></sec></sec><sec id="section30-58841"><title>6. Perspectives</title><p>Bare IONPs are currently employed in an increasing number of clinical trials. In the next decade, we will see them settle into clinical practice for imaging-based diagnosis for a wide range of diseases. One of the main entries of IONPs into the scene of medical application will surely come from their functionalization possibilities. These will provide them with the capacity to target specific cells within the body, and hence develop specific therapies and diagnostic tools. The main advantages of using nanocarriers for specific drug delivery are the reduction of side effects, potential drug resistance and increased drug payload. As unique targeted nanocarriers can deliver hundreds of small drug molecules, clinical practices shall be adapted to incorporate these new strategies. They should include treatment protocols personalized by choosing appropriate formulations with defined targeting moieties and drug loads. The multifunctionalization of IONPs opens the door to multimodal therapeutic approaches by combining the dual effects of magnetic hyperthermia and chemotherapy, using multiple drugs in the same IONP formulation. Additionally, functionalization of IONPs will allow researchers to tune and optimize IONPs' biocompatibility, blood half-life and immunogenicity, key parameters required to successfully bring these innovative nanotechnology-based tools from research laboratories to clinics. Overall, the multifunctionalization of IONPs is a critical step. It is most likely that it will be broadly implemented in the near future for new nanoformulations for both diagnosis and therapy.</p><p>In the particular case of IONPs for magnetic hyperthermia, a number of fundamental and practical aspects still require more research. One of these concerns the magnetic and mechanical behaviour of IONPs inside cells: specifically, we refer to lysosomes under dynamic external fields. Although a few theoretical studies addressing this matter have appeared [<xref rid="bibr118-58841" ref-type="bibr">118</xref>], we require specific experimental approaches to confirm their predictions. Additionally, more work needs to be done to determine the actual heating mechanisms under common frequency and field amplitude conditions, and to evaluate the involvement of any other physical phenomena. In this sense, the results from a very recent publication exploring possible damage to the lysosomal membrane by a remotely induced torque over IONPs are particularly encouraging [<xref rid="bibr119-58841" ref-type="bibr">119</xref>]. The role of phonon-mediated heating and its coupling to those biomolecules in the surroundings, or directly linked to IONPs, is now receiving more attention [<xref rid="bibr120-58841" ref-type="bibr">120</xref>]. These studies will enable us to discern whether or not a sizeable macroscopic temperature change is required to have a therapeutic effect. If not, temperature changes on the micro- or nano-scale could be enough to induce cell death or, at least, to sensitize cancer cells to other treatments (chemo/radiotherapy). Finally, the possibility of having magnetic hyperthermia in an MRI machine has been proposed [<xref rid="bibr121-58841" ref-type="bibr">121</xref>&#x02013;<xref rid="bibr122-58841" ref-type="bibr">122</xref>], but no clear steps have been taken to further develop this appealing idea.</p></sec></body><back><ack><title>7. Acknowledgments</title><p>We are especially grateful to the Health Research Fund (Fondo de Investigaciones Sanitarias, FIS) from the Carlos III Health Institute (PI10/01069 and CP11/00147 (AAS) and PI11/00537 (CBI)). AAS is a recipient of the Miguel Servet Program from Carlos III Health Institute (MS11/00147). DO is grateful for the support received through the AMAROUT-II Marie Curie Action under the European Commission's FP7 PEOPLE-COFUND program and the Research Fund grant from the Royal Society of Chemistry. ALC is grateful for the financial support received through the EU-FP7 MULTIFUN project (no. 262943), the Spanish Ministerio de Econom&#x000ed;a y Competitividad (BIO2012&#x02013;34835), the European Commission International Reintegration Grant (IRG-246688) and the Marie Curie COFUND &#x0201c;AMAROUT-Europe&#x0201d; Programme.</p></ack><sec id="section32-58841" sec-type="COI-statement"><title>8. Compliance with ethical research standards</title><p>Authors have no conflict of interest to declare. No part of this study was performed on any human or animal subject.</p></sec><ref-list><title>References</title><ref id="bibr1-58841"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>KM</given-names></name></person-group>
<article-title>Biomedical nanomagnetics: A spin through possibilities in imaging, diagnostics, and therapy</article-title>. <source>IEEE Trans. Magn.</source>
<volume>46</volume>, <fpage>2523</fpage>&#x02013;<lpage>2558</lpage> (2010).</mixed-citation></ref><ref id="bibr2-58841"><label>[2]</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Coey</surname><given-names>JMD</given-names></name></person-group>
<source>Magnetism and Magnetic Materials</source>. <publisher-name>Cambridge University Press</publisher-name>
<year>2010</year>.</mixed-citation></ref><ref id="bibr3-58841"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>D</given-names></name><name><surname>Hyeon</surname><given-names>T.</given-names></name></person-group>
<article-title>Chemical design of biocompatible iron oxide nanoparticles for medical applications</article-title>. <source>Small [Internet]</source>
<volume>9</volume>(<issue>9&#x02013;10</issue>), <fpage>1450</fpage>&#x02013;<lpage>1466</lpage> (<year>2013</year>). Available from: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/smll.201202111">http://dx.doi.org/10.1002/smll.201202111</ext-link>.</mixed-citation></ref><ref id="bibr4-58841"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baaziz</surname><given-names>W</given-names></name><name><surname>Pichon</surname><given-names>BP</given-names></name><name><surname>Fleutot</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Magnetic iron oxide nanoparticles: Reproducible tuning of the size and nanosized-dependent composition, defects, and spin canting</article-title>. <source>J. Phys. Chem. C.</source>
<volume>118</volume>(<issue>7</issue>), <fpage>3795</fpage>&#x02013;<lpage>3810</lpage>. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-84894560846&#x00026;partnerID=40&#x00026;md5=f738e89fe887bd8209d8a92fb3de1a7d">http://www.scopus.com/inward/record.url?eid=2-s2.0-84894560846&#x00026;partnerID=40&#x00026;md5=f738e89fe887bd8209d8a92fb3de1a7d</ext-link>. Accessed on 21 Jan 2014.</mixed-citation></ref><ref id="bibr5-58841"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Q</given-names></name><name><surname>Yuan</surname><given-names>T</given-names></name><name><surname>Yan</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>One-pot synthesis of size-and morphology-controlled 1-D iron oxide nanochains with manipulated magnetic properties</article-title>. <source>Chem. Commun.</source>
<volume>50</volume>(<issue>2</issue>), <fpage>201</fpage>&#x02013;<lpage>203</lpage> (<year>2014</year>). Available from: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-84889034764&#x00026;partnerID=40&#x00026;md5=409176aec077443f92e6d731dd0437f7">http://www.scopus.com/inward/record.url?eid=2-s2.0-84889034764&#x00026;partnerID=40&#x00026;md5=409176aec077443f92e6d731dd0437f7</ext-link>. Accessed on 23 Oct 2013.</mixed-citation></ref><ref id="bibr6-58841"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Dong</surname><given-names>WF</given-names></name><name><surname>Sun</surname><given-names>HB</given-names></name></person-group>
<article-title>Multifunctional superparamagnetic iron oxide nanoparticles: Design, synthesis and biomedical photonic applications</article-title>. <source>Nanoscale</source>
<volume>5</volume>, <fpage>7664</fpage>&#x02013;<lpage>7684</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23877222</pub-id></mixed-citation></ref><ref id="bibr7-58841"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geraldes</surname><given-names>CF</given-names></name><name><surname>Laurent</surname><given-names>S.</given-names></name></person-group>
<article-title>Classification and basic properties of contrast agents for magnetic resonance imaging</article-title>. <source>Contrast Media Mol. Imaging</source>
<volume>4</volume>(<issue>1</issue>), <fpage>1</fpage>&#x02013;<lpage>23</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19156706</pub-id></mixed-citation></ref><ref id="bibr8-58841"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puri</surname><given-names>IK</given-names></name><name><surname>Ganguly</surname><given-names>R.</given-names></name></person-group>
<article-title>Particle transport in therapeutic magnetic fields</article-title>. <source>Annual Review of Fluid Mechanics</source>
<volume>46</volume>, <fpage>407</fpage>&#x02013;<lpage>440</lpage> (<year>2014</year>).</mixed-citation></ref><ref id="bibr9-58841"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barry</surname><given-names>SE</given-names></name></person-group>
<article-title>Challenges in the development of magnetic particles for therapeutic applications</article-title>. <source>Int. J. Hyperth.</source>
<volume>24</volume>(<issue>6</issue>), <fpage>451</fpage>&#x02013;<lpage>466</lpage> (2008).</mixed-citation></ref><ref id="bibr10-58841"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name></person-group>
<article-title>Size and shape effects on diffusion and absorption of colloidal particles near a partially absorbing sphere: Implications for uptake of nanoparticles in animal cells</article-title>. <source>Phys. Rev. E -Stat. Nonlinear, Soft Matter Phys.</source>
<volume>78</volume>(<issue>6</issue>) (<year>2008</year>).</mixed-citation></ref><ref id="bibr11-58841"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X.</given-names></name></person-group>
<article-title>Size and shape effects on receptor-mediated endocytosis of nanoparticles</article-title>. <source>J. Appl. Phys.</source>
<volume>111</volume>(<issue>2</issue>) (<year>2012</year>).</mixed-citation></ref><ref id="bibr12-58841"><label>[12]</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Guimar&#x000e3;es</surname><given-names>AP</given-names></name></person-group>
<article-title>Principles of Nanomagnetism</article-title>. <source>NanoScience and Nanotechnology series</source>, <publisher-name>Springer.</publisher-name> (<year>2009</year>).</mixed-citation></ref><ref id="bibr13-58841"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowburn</surname><given-names>RP</given-names></name><name><surname>Koltsov</surname><given-names>DK</given-names></name><name><surname>Adeyeye</surname><given-names>AO</given-names></name><name><surname>Welland</surname><given-names>ME</given-names></name><name><surname>Tricker</surname><given-names>DM</given-names></name></person-group>
<article-title>Single-domain circular nanomagnets</article-title>. <source>Phys. Rev. Lett.</source>
<volume>83</volume>, <fpage>1042</fpage>&#x02013;<lpage>1045</lpage> (<year>1999</year>).</mixed-citation></ref><ref id="bibr14-58841"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aharoni</surname><given-names>A.</given-names></name></person-group>
<article-title>The concept of single-domain particle</article-title>. <source>IEEE Trans. Magn.</source>
<volume>27</volume>, <fpage>4775</fpage>&#x02013;<lpage>4777</lpage> (1991).</mixed-citation></ref><ref id="bibr15-58841"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name></person-group>
<article-title>Size and shape effects on diffusion and absorption of colloidal particles near a partially absorbing sphere: Implications for uptake of nanoparticles in animal cells</article-title>. <source>Phys. Rev. E -Stat. Nonlinear, Soft Matter Phys.</source>
<volume>78</volume>(<issue>6</issue>) (<year>2008</year>).</mixed-citation></ref><ref id="bibr16-58841"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dasgupta</surname><given-names>S</given-names></name><name><surname>Auth</surname><given-names>T</given-names></name><name><surname>Gompper</surname><given-names>G.</given-names></name></person-group>
<article-title>Shape and orientation matter for the cellular uptake of nonspherical particles</article-title>. <source>Nano Lett.</source>
<volume>14</volume>(<issue>2</issue>), <fpage>687</fpage>&#x02013;<lpage>693</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24383757</pub-id></mixed-citation></ref><ref id="bibr17-58841"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>H.</given-names></name></person-group>
<article-title>Probing mechanical principles of cell-nanomaterial interactions</article-title>. <source>J. Mech. Phys. Solids.</source>
<volume>62</volume>(<issue>1</issue>), <fpage>312</fpage>&#x02013;<lpage>339</lpage> (<year>2014</year>.</mixed-citation></ref><ref id="bibr18-58841"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>von dem Bussche</surname><given-names>A</given-names></name><name><surname>Hurt</surname><given-names>RH</given-names></name><name><surname>Kane</surname><given-names>AB</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name></person-group>
<article-title>Cell entry of one-dimensional nanomaterials occurs by tip recognition and rotation</article-title>. <source>Nat. Nano.</source>
<volume>6</volume>(<issue>11</issue>), <fpage>714</fpage>&#x02013;<lpage>719</lpage> (<year>2011</year>).</mixed-citation></ref><ref id="bibr19-58841"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toy</surname><given-names>R</given-names></name><name><surname>Peiris</surname><given-names>PM</given-names></name><name><surname>Ghaghada</surname><given-names>KB</given-names></name><name><surname>Karathanasis</surname><given-names>E.</given-names></name></person-group>
<article-title>Shaping cancer nanomedicine: The effect of particle shape on the in vivo journey of nanoparticles</article-title>. <source>Nanomedicine (Lond.)</source>
<volume>9</volume>(<issue>1</issue>), <fpage>121</fpage>&#x02013;<lpage>134</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24354814</pub-id></mixed-citation></ref><ref id="bibr20-58841"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomb&#x000e1;cz</surname><given-names>E</given-names></name><name><surname>Ill&#x000e9;s</surname><given-names>E</given-names></name><name><surname>Majzik</surname><given-names>A</given-names></name><name><surname>Hajd&#x000fa;</surname><given-names>A</given-names></name><name><surname>Rideg</surname><given-names>N</given-names></name><name><surname>Szekeres</surname><given-names>M.</given-names></name></person-group>
<article-title>Ageing in the inorganic nanoworld: Example of magnetite nanoparticles in aqueous medium</article-title>. <source>Croat. Chem. Acta.</source>
<volume>80</volume>, <fpage>503</fpage>&#x02013;<lpage>515</lpage> (<year>2007</year>).</mixed-citation></ref><ref id="bibr21-58841"><label>[21]</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kosmulski</surname><given-names>M.</given-names></name></person-group>
<source>Chemical Properties of Material Surfaces</source>. <publisher-name>CRC Press</publisher-name>
<year>2001</year>.</mixed-citation></ref><ref id="bibr22-58841"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Portney</surname><given-names>NG</given-names></name><etal/></person-group>
<article-title>Zeta potential: A surface electrical characteristic to probe the interaction of nanoparticles with normal and cancer human breast epithelial cells</article-title>. <source>Biomed. Microdevices</source>
<volume>10</volume>(<issue>2</issue>), <fpage>321</fpage>&#x02013;<lpage>328</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18165903</pub-id></mixed-citation></ref><ref id="bibr23-58841"><label>[23]</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>RJ</given-names></name></person-group>
<source>Colloid Science: Zeta Potential in Colloid Science: Principles and Applications</source>. <publisher-name>Acadedmic Press</publisher-name>
<year>1981</year>.</mixed-citation></ref><ref id="bibr24-58841"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>C</given-names></name><name><surname>Wells</surname><given-names>S</given-names></name><name><surname>Charles</surname><given-names>S CA</given-names></name></person-group>
<article-title>Dextran and albumin derivatised iron oxide nanoparticles: Influence on fibroblasts in vitro</article-title>. <source>Biomaterials</source>
<volume>24</volume>, <fpage>4551</fpage>&#x02013;<lpage>4557</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">12950997</pub-id></mixed-citation></ref><ref id="bibr25-58841"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riegler</surname><given-names>J</given-names></name><name><surname>Liew</surname><given-names>A</given-names></name><name><surname>Hynes</surname><given-names>SO</given-names></name><etal/></person-group>
<article-title>Superparamagnetic iron oxide nanoparticle targeting of MSCs in vascular injury</article-title>. <source>Biomaterials</source>
<volume>34</volume>(<issue>8</issue>), <fpage>1987</fpage>&#x02013;<lpage>94</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23237516</pub-id></mixed-citation></ref><ref id="bibr26-58841"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauch</surname><given-names>J</given-names></name><name><surname>Kolch</surname><given-names>W</given-names></name><name><surname>Laurent</surname><given-names>S</given-names></name><name><surname>Mahmoudi</surname><given-names>M.</given-names></name></person-group>
<article-title>Big signals from small particles: Regulation of cell signaling pathways by nanoparticles</article-title>. <source>Chem. Rev.</source>
<volume>113</volume>, <fpage>3391</fpage>&#x02013;<lpage>3406</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23428231</pub-id></mixed-citation></ref><ref id="bibr27-58841"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luengo</surname><given-names>Y</given-names></name><name><surname>Nardecchia</surname><given-names>S</given-names></name><name><surname>Morales</surname><given-names>MP</given-names></name><name><surname>Serrano</surname><given-names>MC</given-names></name></person-group>
<article-title>Different cell responses induced by exposure to maghemite nanoparticles</article-title>. <source>Nanoscale</source>
<volume>5</volume>(<issue>23</issue>), <fpage>11428</fpage>&#x02013;<lpage>11437</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23963338</pub-id></mixed-citation></ref><ref id="bibr28-58841"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahmoudi</surname><given-names>M</given-names></name><name><surname>Quinlan-Pluck</surname><given-names>F</given-names></name><name><surname>Monopoli</surname><given-names>MP</given-names></name><etal/></person-group>
<article-title>Influence of the physiochemical properties of superparamagnetic iron oxide nanoparticles on amyloid &#x003b2; protein fibrillation in solution</article-title>. <source>ACS Chem. Neurosci.</source>
<volume>4</volume>(<issue>3</issue>), <fpage>475</fpage>&#x02013;<lpage>485</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23509983</pub-id></mixed-citation></ref><ref id="bibr29-58841"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>CW</given-names></name></person-group>
<article-title>Surface properties of superparamagnetic iron oxide MR contrast agents: Ferumoxides, ferumoxtran, ferumoxsil</article-title>. <source>Magn. Reson. Imaging</source>
<volume>13</volume>(<issue>5</issue>), <fpage>675</fpage>&#x02013;<lpage>691</lpage> (<year>1995</year>).<pub-id pub-id-type="pmid">8569442</pub-id></mixed-citation></ref><ref id="bibr30-58841"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zorko</surname><given-names>M</given-names></name><name><surname>Langel</surname><given-names>&#x000dc;.</given-names></name></person-group>
<article-title>Cell-penetrating peptides: Mechanism and kinetics of cargo delivery</article-title>. <source>Adv. Drug Deliv. Rev.</source>
<volume>57</volume>, <fpage>529</fpage>&#x02013;<lpage>545</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15722162</pub-id></mixed-citation></ref><ref id="bibr31-58841"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wadia</surname><given-names>JS</given-names></name><name><surname>Dowdy</surname><given-names>SF</given-names></name></person-group>
<article-title>Protein transduction technology</article-title>. <source>Curr. Opin. Biotechnol.</source>
<volume>13</volume>, <fpage>52</fpage>&#x02013;<lpage>56</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">11849958</pub-id></mixed-citation></ref><ref id="bibr32-58841"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Kircher</surname><given-names>MF</given-names></name><name><surname>Josephson</surname><given-names>L</given-names></name><name><surname>Weissleder</surname><given-names>R.</given-names></name></person-group>
<article-title>Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake</article-title>. <source>Bioconjug. Chem.</source>
<volume>13</volume>(<issue>4</issue>), <fpage>840</fpage>&#x02013;<lpage>844</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">12121140</pub-id></mixed-citation></ref><ref id="bibr33-58841"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>AL</given-names></name><name><surname>Bernas</surname><given-names>LM</given-names></name><name><surname>Rutt</surname><given-names>BK</given-names></name><name><surname>Foster</surname><given-names>PJ</given-names></name><name><surname>Gillies</surname><given-names>ER</given-names></name></person-group>
<article-title>Enhanced cell uptake of superparamagnetic iron oxide nanoparticles functionalized with dendritic guanidines</article-title>. <source>Bioconjug. Chem.</source>
<volume>19</volume>(<issue>12</issue>), <fpage>2375</fpage>&#x02013;<lpage>2384</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">19053308</pub-id></mixed-citation></ref><ref id="bibr34-58841"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavalli</surname><given-names>S</given-names></name><name><surname>Carbajo</surname><given-names>D</given-names></name><name><surname>Acosta</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Efficient &#x003b3;-amino-proline-derived cell penetrating peptide&#x02013;superparamagnetic iron oxide nanoparticle conjugates via aniline-catalyzed oxime chemistry as bimodal imaging nanoagents</article-title>. <source>Chem. Commun.</source>
<volume>48</volume>, <fpage>5322</fpage>&#x02013;<lpage>5324</lpage> (<year>2012</year>).</mixed-citation></ref><ref id="bibr35-58841"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>E</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name><name><surname>Tashiro</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Tumour lineagehoming cell-penetrating peptides as anticancer molecular delivery systems</article-title>. <source>Nat. Commun.</source>
<volume>3</volume>(<issue>951</issue>) (<year>2012</year>).</mixed-citation></ref><ref id="bibr36-58841"><label>[36]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svensen</surname><given-names>N</given-names></name><name><surname>Walton</surname><given-names>JG</given-names></name><name><surname>Bradley</surname><given-names>M.</given-names></name></person-group>
<article-title>Peptides for cell-selective drug delivery</article-title>. <source>Trends Pharmacol. Sci.</source>
<volume>33</volume>(<issue>4</issue>), <fpage>186</fpage>&#x02013;<lpage>192</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22424670</pub-id></mixed-citation></ref><ref id="bibr37-58841"><label>[37]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Mehta</surname><given-names>RR</given-names></name><name><surname>Lekmine</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells</article-title>. <source>Mol. Cancer Ther.</source>
<volume>8</volume>(<issue>10</issue>), <fpage>2947</fpage>&#x02013;<lpage>2958</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19808975</pub-id></mixed-citation></ref><ref id="bibr38-58841"><label>[38]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warso</surname><given-names>MA</given-names></name><name><surname>Richards</surname><given-names>JM</given-names></name><name><surname>Mehta</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours</article-title>. <source>Br. J. Cancer</source>
<volume>108</volume>(<issue>5</issue>), <fpage>1061</fpage>&#x02013;<lpage>1070</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23449360</pub-id></mixed-citation></ref><ref id="bibr39-58841"><label>[39]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reichert</surname><given-names>JM</given-names></name><name><surname>Valge-Archer</surname><given-names>VE</given-names></name></person-group>
<article-title>Antibody cancer therapeutics</article-title>. <source>Nat. Rev. Drug Discov</source>. <volume>6</volume>, <fpage>349</fpage>&#x02013;<lpage>356</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17431406</pub-id></mixed-citation></ref><ref id="bibr40-58841"><label>[40]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>HW</given-names></name><name><surname>Josephson</surname><given-names>L</given-names></name><name><surname>Petrovsky</surname><given-names>A</given-names></name><name><surname>Weissleder</surname><given-names>R</given-names></name><name><surname>Bogdanov</surname><given-names>A</given-names><suffix>Jr.</suffix></name></person-group>
<article-title>Magnetic resonance imaging of inducible E-selectin expression in human endothelial cell culture</article-title>. <source>Bioconjug. Chem.</source>
<volume>13</volume>(<issue>1</issue>), <fpage>122</fpage>&#x02013;<lpage>127</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">11792187</pub-id></mixed-citation></ref><ref id="bibr41-58841"><label>[41]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slamon</surname><given-names>DJ</given-names></name><name><surname>Clark</surname><given-names>GM</given-names></name><name><surname>Wong</surname><given-names>SG</given-names></name><name><surname>Levin</surname><given-names>WJ</given-names></name><name><surname>Ullrich</surname><given-names>A</given-names></name><name><surname>McGuire</surname><given-names>WL</given-names></name></person-group>
<article-title>Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene</article-title>. <source>Science</source>
<volume>235</volume>(<issue>4785</issue>), <fpage>177</fpage>&#x02013;<lpage>182</lpage> (<year>1987</year>).<pub-id pub-id-type="pmid">3798106</pub-id></mixed-citation></ref><ref id="bibr42-58841"><label>[42]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huh</surname><given-names>Y</given-names></name><name><surname>Jun</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals</article-title>. <source>J. Am. Chem. Soc.</source>
<volume>127</volume>(<issue>35</issue>), <fpage>12387</fpage>&#x02013;<lpage>12391</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">16131220</pub-id></mixed-citation></ref><ref id="bibr43-58841"><label>[43]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dilnawaz</surname><given-names>F</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Mohanty</surname><given-names>C</given-names></name><name><surname>Sahoo</surname><given-names>SK</given-names></name></person-group>
<article-title>Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy</article-title>. <source>Biomaterials</source>
<volume>31</volume>(<issue>13</issue>), <fpage>3694</fpage>&#x02013;<lpage>3706</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20144478</pub-id></mixed-citation></ref><ref id="bibr44-58841"><label>[44]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vigor</surname><given-names>KL</given-names></name><name><surname>Kyrtatos</surname><given-names>PG</given-names></name><name><surname>Minogue</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Nanoparticles functionalized with recombinant single chain Fv antibody fragments (scFv) for the magnetic resonance imaging of cancer cells</article-title>. <source>Biomaterials</source>
<volume>31</volume>(<issue>6</issue>), <fpage>1307</fpage>&#x02013;<lpage>1315</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">19889453</pub-id></mixed-citation></ref><ref id="bibr45-58841"><label>[45]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piraux</surname><given-names>H</given-names></name><name><surname>Hai</surname><given-names>J</given-names></name><name><surname>Verbeke</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Transferrin receptor-1 iron-acquisition pathway &#x02013; Synthesis, kinetics, thermodynamics and rapid cellular internalization of a holotransferrin-maghemite nanoparticle construct</article-title>. <source>Biochim. Biophys. Acta &#x02013; Gen. Subj.</source>
<volume>1830</volume>(<issue>8</issue>), <fpage>4254</fpage>&#x02013;<lpage>4264</lpage> (<year>2013</year>).</mixed-citation></ref><ref id="bibr46-58841"><label>[46]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montet</surname><given-names>X</given-names></name><name><surname>Montet-Abou</surname><given-names>K</given-names></name><name><surname>Reynolds</surname><given-names>F</given-names></name><name><surname>Weissleder</surname><given-names>R</given-names></name><name><surname>Josephson</surname><given-names>L.</given-names></name></person-group>
<article-title>Nanoparticle imaging of integrins on tumor cells</article-title>. <source>Neoplasia</source>
<volume>8</volume>(<issue>3</issue>), <fpage>214</fpage>&#x02013;<lpage>222</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16611415</pub-id></mixed-citation></ref><ref id="bibr47-58841"><label>[47]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Ultrasmall c(RGDyK)-coated Fe 3 O 4 nanoparticles and their specific targeting to integrin r v 3-rich tumor cells</article-title>. <source>J. Am. Chem. Soc.</source>
<volume>130</volume>(<issue>24</issue>), <fpage>7542</fpage>&#x02013;<lpage>7543</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18500805</pub-id></mixed-citation></ref><ref id="bibr48-58841"><label>[48]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kizilel</surname><given-names>S</given-names></name><name><surname>Nazli</surname><given-names>C</given-names></name><name><surname>Ergenc</surname></name><name><surname>Acar</surname><given-names>HY</given-names></name></person-group>
<article-title>RGDS-functionalized polyethylene glycol hydrogel-coated magnetic iron oxide nanoparticles enhance specific intracellular uptake by HeLa cells</article-title>. <source>Int. J. Nanomedicine</source>
<volume>7</volume>, <fpage>1903</fpage>&#x02013;<lpage>1920</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22619531</pub-id></mixed-citation></ref><ref id="bibr49-58841"><label>[49]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyons</surname><given-names>S</given-names></name><name><surname>O'Neal</surname><given-names>J</given-names></name><name><surname>Sontheimer</surname><given-names>H.</given-names></name></person-group>
<article-title>Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin</article-title>. <source>Glia</source>
<volume>39</volume>, <fpage>162</fpage>&#x02013;<lpage>173</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">12112367</pub-id></mixed-citation></ref><ref id="bibr50-58841"><label>[50]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Veiseh</surname><given-names>O</given-names></name><name><surname>Gunn</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes</article-title>. <source>Small</source>
<volume>4</volume>(<issue>3</issue>), <fpage>372</fpage>&#x02013;<lpage>379</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18232053</pub-id></mixed-citation></ref><ref id="bibr51-58841"><label>[51]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Destouches</surname><given-names>D</given-names></name><name><surname>El Khoury</surname><given-names>D</given-names></name><name><surname>Hamma-Kourbali</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin</article-title>. <source>PLoS One</source>
<volume>3</volume>, <fpage>e2518</fpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18560571</pub-id></mixed-citation></ref><ref id="bibr52-58841"><label>[52]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Destouches</surname><given-names>D</given-names></name><name><surname>Page</surname><given-names>N</given-names></name><name><surname>Hamma-Kourbali</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>A simple approach to cancer therapy afforded by multivalent pseudopeptides that target cell-surface nucleoproteins</article-title>. <source>Cancer Res.</source>
<volume>71</volume>(<issue>9</issue>), <fpage>3296</fpage>&#x02013;<lpage>3305</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21415166</pub-id></mixed-citation></ref><ref id="bibr53-58841"><label>[53]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Shukoor</surname><given-names>MI</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Smart multifunctional nanostructure for targeted cancer chemotherapy and magnetic resonance imaging</article-title>. <source>ACS Nano</source>
<volume>5</volume>(<issue>10</issue>), <fpage>7866</fpage>&#x02013;<lpage>7873</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21888350</pub-id></mixed-citation></ref><ref id="bibr54-58841"><label>[54]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sturge</surname><given-names>J</given-names></name><name><surname>Wienke</surname><given-names>D</given-names></name><name><surname>East</surname><given-names>L</given-names></name><name><surname>Jones</surname><given-names>GE</given-names></name><name><surname>Isacke</surname><given-names>CM</given-names></name></person-group>
<article-title>GPI-anchored uPAR requires Endo180 for rapid directional sensing during chemotaxis</article-title>. <source>J. Cell Biol.</source>
<volume>162</volume>(<issue>5</issue>), <fpage>789</fpage>&#x02013;<lpage>794</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">12952933</pub-id></mixed-citation></ref><ref id="bibr55-58841"><label>[55]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moros</surname><given-names>M</given-names></name><name><surname>Hernaez</surname><given-names>B</given-names></name><name><surname>Garet</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Monosaccharides versus PEG-functionalized NPs: Influence in the cellular uptake</article-title>. <source>ACS Nano</source>
<volume>6</volume>(<issue>2</issue>), <fpage>1565</fpage>&#x02013;<lpage>1577</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22214244</pub-id></mixed-citation></ref><ref id="bibr56-58841"><label>[56]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valero</surname><given-names>E</given-names></name><name><surname>Tambalo</surname><given-names>S</given-names></name><name><surname>Marzola</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Magnetic nanoparticles-templated assembly of protein subunits: A new platform for carbohydrate-based MRI nanoprobes</article-title>. <source>J. Am. Chem. Soc.</source>
<volume>133</volume>(<issue>13</issue>), <fpage>4889</fpage>&#x02013;<lpage>4895</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21384882</pub-id></mixed-citation></ref><ref id="bibr57-58841"><label>[57]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weitman</surname><given-names>SD</given-names></name><name><surname>Lark</surname><given-names>RH</given-names></name><name><surname>Coney</surname><given-names>LR</given-names></name><etal/></person-group>
<article-title>Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues</article-title>. <source>Cancer Res.</source>
<volume>52</volume>(<issue>12</issue>), <fpage>3396</fpage>&#x02013;<lpage>3401</lpage> (<year>1992</year>).<pub-id pub-id-type="pmid">1596899</pub-id></mixed-citation></ref><ref id="bibr58-58841"><label>[58]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Low</surname><given-names>PS</given-names></name><name><surname>Henne</surname><given-names>W a</given-names></name><name><surname>Doorneweerd</surname><given-names>DD</given-names></name></person-group>
<article-title>Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases</article-title>. <source>Acc. Chem. Res.</source>
<volume>41</volume>(<issue>1</issue>), <fpage>120</fpage>&#x02013;<lpage>129</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">17655275</pub-id></mixed-citation></ref><ref id="bibr59-58841"><label>[59]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><etal/></person-group>
<article-title>Tumor selectivity of stealth multi-functionalized superparamagnetic iron oxide nanoparticles</article-title>. <source>Int. J. Pharm.</source>
<volume>404</volume>(<issue>1&#x02013;2</issue>), <fpage>180</fpage>&#x02013;<lpage>190</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21087660</pub-id></mixed-citation></ref><ref id="bibr60-58841"><label>[60]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sapsford</surname><given-names>KE</given-names></name><name><surname>Algar</surname><given-names>WR</given-names></name><name><surname>Berti</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Functionalizing nanoparticles with biological molecules: Developing chemistries that facilitate nanotechnology</article-title>. <source>Chem. Rev.</source>
<volume>113</volume>(<issue>3</issue>), <fpage>1904</fpage>&#x02013;<lpage>2074</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23432378</pub-id></mixed-citation></ref><ref id="bibr61-58841"><label>[61]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almeida</surname><given-names>JP</given-names></name><name><surname>Chen</surname><given-names>AL</given-names></name><name><surname>Foster</surname><given-names>A</given-names></name><name><surname>Drezek</surname><given-names>R.</given-names></name></person-group>
<article-title>In vivo biodistribution of nanoparticles</article-title>. <source>Nanomedicine</source>
<volume>6</volume>(<issue>5</issue>), <fpage>815</fpage>&#x02013;<lpage>835</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21793674</pub-id></mixed-citation></ref><ref id="bibr62-58841"><label>[62]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hillaireau</surname><given-names>H</given-names></name><name><surname>Couvreur</surname><given-names>P.</given-names></name></person-group>
<article-title>Nanocarriers' entry into the cell: Relevance to drug delivery</article-title>. <source>Cell. Mol. Life Sci.</source>
<volume>66</volume>(<issue>17</issue>), <fpage>2873</fpage>&#x02013;<lpage>2896</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19499185</pub-id></mixed-citation></ref><ref id="bibr63-58841"><label>[63]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nel</surname><given-names>A</given-names></name><name><surname>Xia</surname><given-names>T</given-names></name><name><surname>Madler</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>N.</given-names></name></person-group>
<article-title>Toxic potential of materials at the nanolevel</article-title>. <source>Science</source>
<volume>311</volume>(<issue>5761</issue>), <fpage>622</fpage>&#x02013;<lpage>627</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16456071</pub-id></mixed-citation></ref><ref id="bibr64-58841"><label>[64]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>AK</given-names></name><name><surname>Curtis</surname><given-names>AS</given-names></name></person-group>
<article-title>Surface modified superparamagnetic nanoparticles for drug delivery: Interaction studies with human fibroblasts in culture</article-title>. <source>J Mater. Sci Mater. Med.</source>
<volume>15</volume>(<issue>4</issue>), <fpage>493</fpage>&#x02013;<lpage>496</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15332623</pub-id></mixed-citation></ref><ref id="bibr65-58841"><label>[65]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Jenkins</surname><given-names>GJS</given-names></name><name><surname>Asadi</surname><given-names>R</given-names></name><name><surname>Doak</surname><given-names>SH</given-names></name></person-group>
<article-title>Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION)</article-title>. <source>Nano Rev.</source>
<volume>1</volume> (<year>2010</year>).</mixed-citation></ref><ref id="bibr66-58841"><label>[66]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahmoudi</surname><given-names>M</given-names></name><name><surname>Simchi</surname><given-names>A</given-names></name><name><surname>Imani</surname><given-names>M</given-names></name><name><surname>Milani</surname><given-names>AS SP</given-names></name></person-group>
<article-title>An in vitro study of bare and poly(ethylene-glycol)-co-fumarate-coated superparamagnetic iron oxide nanoparticles: A new toxicity identification procedure</article-title>. <source>Nanotechnology</source>
<volume>20</volume>(<issue>22</issue>), <fpage>225104</fpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19433870</pub-id></mixed-citation></ref><ref id="bibr67-58841"><label>[67]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>C</given-names></name><name><surname>Wells</surname><given-names>S</given-names></name><name><surname>Charles</surname><given-names>S</given-names></name><name><surname>Aitchison</surname><given-names>G CA</given-names></name></person-group>
<article-title>Cell response to dextran-derivatised iron oxide nanoparticles post internalization</article-title>. <source>Biomaterials</source>
<volume>25</volume>(<issue>23</issue>), <fpage>5405</fpage>&#x02013;<lpage>5413</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15130725</pub-id></mixed-citation></ref><ref id="bibr68-58841"><label>[68]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Mao</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>M.</given-names></name></person-group>
<article-title>Toxic effects of iron oxide nanoparticles on human umbilical vein endothelial cells</article-title>. <source>Int. J. Nanomedicine</source>
<volume>5</volume>, <fpage>358</fpage>&#x02013;<lpage>399</lpage> (<year>2010</year>).</mixed-citation></ref><ref id="bibr69-58841"><label>[69]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>DM</given-names></name><name><surname>Hsiao</surname><given-names>JK</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name><etal/></person-group>
<article-title>The promotion of human mesenchymal stem cell proliferation by superparamagnetic iron oxide nanoparticles</article-title>. <source>Biomaterials</source>
<volume>30</volume>(<issue>22</issue>), <fpage>3645</fpage>&#x02013;<lpage>3651</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19359036</pub-id></mixed-citation></ref><ref id="bibr70-58841"><label>[70]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burton</surname><given-names>L</given-names></name><name><surname>Berganos</surname><given-names>R</given-names></name><name><surname>Shen</surname><given-names>B</given-names></name><name><surname>Chin</surname><given-names>FT</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: A PET radiopharmaceutical agent for imaging &#x003b1;(v)&#x003b2;(3) integrin levels</article-title>. <source>Radiology</source>
<volume>260</volume>(<issue>1</issue>), <fpage>182</fpage>&#x02013;<lpage>191</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21502381</pub-id></mixed-citation></ref><ref id="bibr71-58841"><label>[71]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewinski</surname><given-names>N</given-names></name><name><surname>Colvin</surname><given-names>V</given-names></name><name><surname>Drezek</surname><given-names>R.</given-names></name></person-group>
<article-title>Cytotoxicity of nanoparticles</article-title>. <source>Small</source>
<volume>4</volume>, <fpage>26</fpage>&#x02013;<lpage>49</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18165959</pub-id></mixed-citation></ref><ref id="bibr72-58841"><label>[72]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffith</surname><given-names>LG</given-names></name><name><surname>Swartz</surname><given-names>MA</given-names></name></person-group>
<article-title>Capturing complex 3D tissue physiology in vitro</article-title>. <source>Nat, Rev, Mol, Cell Biol.</source>
<volume>7</volume>(<issue>3</issue>), <fpage>211</fpage>&#x02013;<lpage>224</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16496023</pub-id></mixed-citation></ref><ref id="bibr73-58841"><label>[73]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JS</given-names></name><name><surname>Yoon</surname><given-names>TJ</given-names></name><name><surname>Yu</surname><given-names>KN</given-names></name><etal/></person-group>
<article-title>Toxicity and tissue distribution of magnetic nanoparticles in mice</article-title>. <source>Toxicol. Sci.</source>
<volume>89</volume>(<issue>1</issue>), <fpage>338</fpage>&#x02013;<lpage>347</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16237191</pub-id></mixed-citation></ref><ref id="bibr74-58841"><label>[74]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>KJ</given-names></name><name><surname>Clyne</surname><given-names>AM</given-names></name></person-group>
<article-title>Dextran and polymer polyethylene glycol (PEG) coating reduce both 5 and 30 nm iron oxide nanoparticle cytotoxicity in 2D and 3D cell culture</article-title>. <source>Int. J. Mol. Sci.</source>
<volume>13</volume>(<issue>5</issue>), <fpage>5554</fpage>&#x02013;<lpage>5570</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22754315</pub-id></mixed-citation></ref><ref id="bibr75-58841"><label>[75]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anzai</surname><given-names>Y</given-names></name><name><surname>Piccoli</surname><given-names>CW</given-names></name><name><surname>Outwater</surname><given-names>EK</given-names></name><etal/></person-group>
<article-title>Radiology for the group evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: Phase III safety and efficacy study</article-title>. <source>Radiology</source>
<volume>228</volume>(<issue>3</issue>), <fpage>777</fpage>&#x02013;<lpage>788</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">12954896</pub-id></mixed-citation></ref><ref id="bibr76-58841"><label>[76]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>AK</given-names></name><name><surname>Gupta</surname><given-names>M.</given-names></name></person-group>
<article-title>Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications</article-title>. <source>Biomaterials</source>
<volume>26</volume>(<issue>18</issue>), <fpage>3995</fpage>&#x02013;<lpage>4021</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">15626447</pub-id></mixed-citation></ref><ref id="bibr77-58841"><label>[77]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clemente-Casares</surname><given-names>X</given-names></name><name><surname>Santamaria</surname><given-names>P.</given-names></name></person-group>
<article-title>Nanomedicine in autoimmunity</article-title>. <source>Immunol Lett.</source>
<volume>158</volume>(<issue>1&#x02013;2</issue>), <fpage>167</fpage>&#x02013;<lpage>174</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24406504</pub-id></mixed-citation></ref><ref id="bibr78-58841"><label>[78]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>JM</given-names></name><name><surname>Shaw</surname><given-names>C</given-names></name><name><surname>Lang</surname><given-names>NN</given-names></name><etal/></person-group>
<article-title>In vivo mononuclear cell tracking using superparamagnetic particles of iron oxide: Feasibility and safety in humans</article-title>. <source>Circ. Cardiovasc. Imaging</source>
<volume>5</volume>(<issue>4</issue>), <fpage>509</fpage>&#x02013;<lpage>517</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22787016</pub-id></mixed-citation></ref><ref id="bibr79-58841"><label>[79]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maccioni</surname><given-names>F</given-names></name><name><surname>Bruni</surname><given-names>A</given-names></name><name><surname>Viscido</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>MR imaging in patients with Crohn disease: Value of T2-versus T1-weighted gadolinium-enhanced MR sequences with use of an oral superparamagnetic contrast agent</article-title>. <source>Radiology</source>
<volume>238</volume>(<issue>2</issue>), <fpage>517</fpage>&#x02013;<lpage>530</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16371574</pub-id></mixed-citation></ref><ref id="bibr80-58841"><label>[80]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Arienzo</surname><given-names>A</given-names></name><name><surname>Scaglione</surname><given-names>G</given-names></name><name><surname>Vicinanza</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Magnetic resonance imaging with ferumoxil, a negative superparamagnetic oral contrast agent, in the evaluation of ulcerative colitis</article-title>. <source>Am. J. Gastroenterol.</source>
<volume>95</volume>(<issue>3</issue>), <fpage>720</fpage>&#x02013;<lpage>724</lpage> (<year>2000</year>).<pub-id pub-id-type="pmid">10710064</pub-id></mixed-citation></ref><ref id="bibr81-58841"><label>[81]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Arienzo</surname><given-names>A</given-names></name><name><surname>Scaglione</surname><given-names>G</given-names></name><name><surname>Bennato</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>The prognostic value, in active ulcerative colitis, of an increased intensity of colonic perivisceral fat signal on magnetic resonance imaging with ferumoxil</article-title>. <source>Am. J. Gastroenterol.</source>
<volume>96</volume>(<issue>2</issue>), <fpage>481</fpage>&#x02013;<lpage>486</lpage> (<year>2001</year>).<pub-id pub-id-type="pmid">11232694</pub-id></mixed-citation></ref><ref id="bibr82-58841"><label>[82]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaglia</surname><given-names>JL</given-names></name><name><surname>Guimaraes</surname><given-names>AR</given-names></name><name><surname>Harisinghani</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients</article-title>. <source>J. Clin. Invest.</source>
<volume>121</volume>(<issue>1</issue>), <fpage>442</fpage>&#x02013;<lpage>445</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">21123946</pub-id></mixed-citation></ref><ref id="bibr83-58841"><label>[83]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vellinga</surname><given-names>MM</given-names></name><name><surname>Vrenken</surname><given-names>H</given-names></name><name><surname>Hulst</surname><given-names>HE</given-names></name><etal/></person-group>
<article-title>Use of ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI to demonstrate diffuse inflammation in the normal-appearing white matter (NAWM) of multiple sclerosis (MS) patients: An exploratory study</article-title>. <source>J. Magn. Reson. Imaging.</source>
<volume>29</volume>, <fpage>774</fpage>&#x02013;<lpage>779</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19306366</pub-id></mixed-citation></ref><ref id="bibr84-58841"><label>[84]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tourdias</surname><given-names>T</given-names></name><name><surname>Roggerone</surname><given-names>S</given-names></name><name><surname>Filippi</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Assessment of disease activity in multiple sclerosis phenotypes with combined gadolinium- and superparamagnetic iron oxide-enhanced MR imaging</article-title>. <source>Radiology</source>
<volume>264</volume>(<issue>1</issue>), <fpage>225</fpage>&#x02013;<lpage>233</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22723563</pub-id></mixed-citation></ref><ref id="bibr85-58841"><label>[85]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eitel</surname><given-names>I</given-names></name><name><surname>Kubusch</surname><given-names>K</given-names></name><name><surname>Strohm</surname><given-names>O</given-names></name><etal/></person-group>
<article-title>Prognostic value and determinants of a hypointense infarct core in T2-weighted cardiac magnetic resonance in acute reperfused ST-elevation-myocardial infarction</article-title>. <source>Circ. Cardiovasc. Imaging.</source>
<volume>4</volume>(<issue>4</issue>), <fpage>354</fpage>&#x02013;<lpage>362</lpage>.<pub-id pub-id-type="pmid">21518773</pub-id></mixed-citation></ref><ref id="bibr86-58841"><label>[86]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Payne</surname><given-names>AR</given-names></name><name><surname>Berry</surname><given-names>C</given-names></name><name><surname>Kellman</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Bright-blood T(2)-weighted MRI has high diagnostic accuracy for myocardial hemorrhage in myocardial infarction: A preclinical validation study in swine</article-title>. <source>Circ. Cardiovasc. Imaging</source>
<volume>4</volume>(<issue>6</issue>), <fpage>738</fpage>&#x02013;<lpage>745</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21930836</pub-id></mixed-citation></ref><ref id="bibr87-58841"><label>[87]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yilmaz</surname><given-names>A</given-names></name><name><surname>Dengler</surname><given-names>MA</given-names></name><name><surname>van der Kuip</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Imaging of myocardial infarction using ultrasmall superparamagnetic iron oxide nanoparticles: A human study using a multi-parametric cardiovascular magnetic resonance imaging approach</article-title>. <source>Eur. Hear. J.</source>
<volume>34</volume>(<issue>6</issue>), <fpage>462</fpage>&#x02013;<lpage>475</lpage> (<year>2012</year>).</mixed-citation></ref><ref id="bibr88-58841"><label>[88]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sigovan</surname><given-names>M</given-names></name><name><surname>Gasper</surname><given-names>W</given-names></name><name><surname>Alley</surname><given-names>HF</given-names></name><name><surname>Owens</surname><given-names>CD</given-names></name><name><surname>Saloner</surname><given-names>D.</given-names></name></person-group>
<article-title>USPIO-enhanced MR angiography of arteriovenous fistulas in patients with renal failure</article-title>. <source>Radiology</source>
<volume>265</volume>(<issue>2</issue>), <fpage>584</fpage>&#x02013;<lpage>590</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22875796</pub-id></mixed-citation></ref><ref id="bibr89-58841"><label>[89]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Degnan</surname><given-names>AJ</given-names></name><name><surname>Patterson</surname><given-names>AJ</given-names></name><name><surname>Tang</surname><given-names>TY</given-names></name><name><surname>Howarth</surname><given-names>SP</given-names></name><name><surname>Gillard</surname><given-names>JH</given-names></name></person-group>
<article-title>Evaluation of ultrasmall superparamagnetic iron oxide-enhanced MRI of carotid atherosclerosis to assess risk of cerebrovascular and cardiovascular events: Follow-up of the ATHEROMA trial</article-title>. <source>Cerebrovasc. Dis.</source>
<volume>34</volume>(<issue>2</issue>), <fpage>169</fpage>&#x02013;<lpage>173</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22922841</pub-id></mixed-citation></ref><ref id="bibr90-58841"><label>[90]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>PM</given-names></name><name><surname>Feindel</surname><given-names>KW</given-names></name><name><surname>Slocombe</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Strongly magnetic iron nanoparticles improve the diagnosis of small tumours in the reticuloendothelial system by magnetic resonance imaging</article-title>. <source>PLoS One</source>
<volume>8</volume>, <fpage>e56572</fpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23437173</pub-id></mixed-citation></ref><ref id="bibr91-58841"><label>[91]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Liao</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>F.</given-names></name></person-group>
<article-title>Diagnostic performance of USPIO-enhanced MRI for lymph-node metastases in different body regions: A meta-analysis</article-title>. <source>Eur. J. Radiol.</source>
<volume>80</volume>(<issue>2</issue>), <fpage>582</fpage>&#x02013;<lpage>589</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20047813</pub-id></mixed-citation></ref><ref id="bibr92-58841"><label>[92]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harisinghani</surname><given-names>MG</given-names></name><name><surname>Barentsz</surname><given-names>J</given-names></name><name><surname>Hahn</surname><given-names>PF</given-names></name><etal/></person-group>
<article-title>Noninvasive detection of clinically occult lymph-node metastases in prostate cancer</article-title>. <source>N. Engl. J. Med.</source>
<volume>348</volume>, <fpage>2491</fpage>&#x02013;<lpage>2499</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">12815134</pub-id></mixed-citation></ref><ref id="bibr93-58841"><label>[93]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heesakkers</surname><given-names>RA</given-names></name><name><surname>Hovels</surname><given-names>AM</given-names></name><name><surname>Jager</surname><given-names>GJ</given-names></name><etal/></person-group>
<article-title>MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: A prospective multicohort study</article-title>. <source>Lancet Oncol</source>. <volume>9</volume>(<issue>9</issue>), <fpage>850</fpage>&#x02013;<lpage>856</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18708295</pub-id></mixed-citation></ref><ref id="bibr94-58841"><label>[94]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ross</surname><given-names>RW</given-names></name><name><surname>Zietman</surname><given-names>AL</given-names></name><name><surname>Xie</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy</article-title>. <source>Clin. Imaging</source>
<volume>33</volume>(<issue>4</issue>), <fpage>301</fpage>&#x02013;<lpage>305</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19559353</pub-id></mixed-citation></ref><ref id="bibr95-58841"><label>[95]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Triantafyllou</surname><given-names>M</given-names></name><name><surname>Studer</surname><given-names>UE</given-names></name><name><surname>Birkhauser</surname><given-names>FD</given-names></name><etal/></person-group>
<article-title>Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer</article-title>. <source>Eur. J. Cancer</source>
<volume>49</volume>(<issue>3</issue>), <fpage>616</fpage>&#x02013;<lpage>624</lpage>.<pub-id pub-id-type="pmid">23084842</pub-id></mixed-citation></ref><ref id="bibr96-58841"><label>[96]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>L</given-names></name><name><surname>Pinder</surname><given-names>SE</given-names></name><name><surname>Douek</surname><given-names>M.</given-names></name></person-group>
<article-title>Deposition of superparamagnetic iron-oxide nanoparticles in axillary sentinel lymph nodes following subcutaneous injection</article-title>. <source>Histopathology</source>
<volume>62</volume>(<issue>3</issue>), <fpage>481</fpage>&#x02013;<lpage>486</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23278862</pub-id></mixed-citation></ref><ref id="bibr97-58841"><label>[97]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motomura</surname><given-names>K</given-names></name><name><surname>Ishitobi</surname><given-names>M</given-names></name><name><surname>Komoike</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>SPIO-enhanced magnetic resonance imaging for the detection of metastases in sentinel nodes localized by computed tomography lymphography in patients with breast cancer</article-title>. <source>Ann. Surg. Oncol.</source>
<volume>18</volume>(<issue>12</issue>), <fpage>3422</fpage>&#x02013;<lpage>3429</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21607775</pub-id></mixed-citation></ref><ref id="bibr98-58841"><label>[98]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motomura</surname><given-names>K</given-names></name><name><surname>Izumi</surname><given-names>T</given-names></name><name><surname>Tateishi</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Correlation between the area of high-signal intensity on SPIO-enhanced MR imaging and the pathologic size of sentinel node metastases in breast cancer patients with positive sentinel nodes</article-title>. <source>BMC Med. Imaging</source>
<volume>13</volume>(<issue>32</issue>) (<year>2013</year>).</mixed-citation></ref><ref id="bibr99-58841"><label>[99]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guimaraes</surname><given-names>AR</given-names></name><name><surname>Tabatabei</surname><given-names>S</given-names></name><name><surname>Dahl</surname><given-names>D</given-names></name><name><surname>McDougal</surname><given-names>WS</given-names></name><name><surname>Weissleder</surname><given-names>R</given-names></name><name><surname>Harisinghani</surname><given-names>MG</given-names></name></person-group>
<article-title>Pilot study evaluating use of lymphotrophic nanoparticle-enhanced magnetic resonance imaging for assessing lymph nodes in renal cell cancer</article-title>. <source>Urology</source>
<volume>71</volume>(<issue>4</issue>), <fpage>708</fpage>&#x02013;<lpage>712</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18295316</pub-id></mixed-citation></ref><ref id="bibr100-58841"><label>[100]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>L</given-names></name><name><surname>Karp</surname><given-names>JM</given-names></name><name><surname>Nobre</surname><given-names>L</given-names></name><name><surname>Langer</surname><given-names>R.</given-names></name></person-group>
<article-title>New opportunities: The use of nanotechnologies to manipulate and track stem cells</article-title>. <source>Cell Stem Cell</source>
<volume>3</volume>(<issue>2</issue>), <fpage>136</fpage>&#x02013;<lpage>146</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18682237</pub-id></mixed-citation></ref><ref id="bibr101-58841"><label>[101]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karussis</surname><given-names>D</given-names></name><name><surname>Karageorgiou</surname><given-names>C</given-names></name><name><surname>Vaknin-Dembinsky</surname><given-names>A</given-names></name><name><surname>Gowda-Kurkalli</surname><given-names>B</given-names></name><name><surname>Gomori</surname><given-names>JM</given-names></name><name><surname>Kassis</surname><given-names>I</given-names></name><name><surname>Bulte</surname><given-names>JW</given-names></name><name><surname>Petrou</surname><given-names>P</given-names></name><name><surname>Ben-Hur</surname><given-names>T</given-names></name><name><surname>Abramsky</surname><given-names>O</given-names></name><name><surname>Slavin</surname><given-names>S.</given-names></name></person-group>
<article-title>Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis</article-title>. <source>Arch. Neurol.</source>
<volume>67</volume>(<issue>10</issue>), <fpage>1187</fpage>&#x02013;<lpage>1194</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20937945</pub-id></mixed-citation></ref><ref id="bibr102-58841"><label>[102]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figdor</surname><given-names>CG</given-names></name><name><surname>de Vries</surname><given-names>IJ</given-names></name><name><surname>Lesterhuis</surname><given-names>WJ</given-names></name><name><surname>Melief</surname><given-names>CJ</given-names></name></person-group>
<article-title>Dendritic cell immunotherapy: Mapping the way</article-title>. <source>Nat. Med.</source>
<volume>10</volume>, <fpage>475</fpage>&#x02013;<lpage>480</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15122249</pub-id></mixed-citation></ref><ref id="bibr103-58841"><label>[103]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Vries</surname><given-names>IJ</given-names></name><name><surname>Krooshoop</surname><given-names>DJ</given-names></name><name><surname>Scharenborg</surname><given-names>NM</given-names></name><etal/></person-group>
<article-title>Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state</article-title>. <source>Cancer Res.</source>
<volume>63</volume>(<issue>1</issue>), <fpage>12</fpage>&#x02013;<lpage>17</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">12517769</pub-id></mixed-citation></ref><ref id="bibr104-58841"><label>[104]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Vries</surname><given-names>IJM</given-names></name><name><surname>Lesterhuis</surname><given-names>WJ</given-names></name><name><surname>Barentsz</surname><given-names>JO</given-names></name><etal/></person-group>
<article-title>Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy</article-title>. <source>Nat. Biotechnol.</source>
<volume>23</volume>(<issue>11</issue>), <fpage>1407</fpage>&#x02013;<lpage>1413</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">16258544</pub-id></mixed-citation></ref><ref id="bibr105-58841"><label>[105]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>McMillan</surname><given-names>JM</given-names></name><name><surname>Liu</surname><given-names>XM</given-names></name><etal/></person-group>
<article-title>Formulation design facilitates magnetic nanoparticle delivery to diseased cells and tissues</article-title>. <source>Nanomedicine (Lond.)</source>
<volume>9</volume>(<issue>3</issue>), <fpage>469</fpage>&#x02013;<lpage>485</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24646020</pub-id></mixed-citation></ref><ref id="bibr106-58841"><label>[106]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Provenzano</surname><given-names>R</given-names></name><name><surname>Schiller</surname><given-names>B</given-names></name><name><surname>Rao</surname><given-names>M</given-names></name><name><surname>Coyne</surname><given-names>D</given-names></name><name><surname>Brenner</surname><given-names>L</given-names></name><name><surname>Pereira</surname><given-names>BJ</given-names></name></person-group>
<article-title>Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients</article-title>. <source>Clin. J. Am. Soc. Nephrol.</source>
<volume>4</volume>(<issue>2</issue>), <fpage>386</fpage>&#x02013;<lpage>393</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19176796</pub-id></mixed-citation></ref><ref id="bibr107-58841"><label>[107]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vadhan-Raj</surname><given-names>S</given-names></name><name><surname>Strauss</surname><given-names>W</given-names></name><name><surname>Ford</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron</article-title>. <source>Am. J. Hematol.</source>
<volume>89</volume>(<issue>1</issue>), <fpage>7</fpage>&#x02013;<lpage>12</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">23983177</pub-id></mixed-citation></ref><ref id="bibr108-58841"><label>[108]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hetzel</surname><given-names>D</given-names></name><name><surname>Strauss</surname><given-names>W</given-names></name><name><surname>Bernard</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Urboniene</surname><given-names>A</given-names></name><name><surname>Allen</surname><given-names>LF</given-names></name></person-group>
<article-title>A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy</article-title>. <source>Am. J. Hematol.</source>
<volume>89</volume>(<issue>6</issue>), <fpage>646</fpage>&#x02013;<lpage>650</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24639149</pub-id></mixed-citation></ref><ref id="bibr109-58841"><label>[109]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macdougall</surname><given-names>IC</given-names></name><name><surname>Strauss</surname><given-names>WE</given-names></name><name><surname>McLaughlin</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Dellanna</surname><given-names>F</given-names></name><name><surname>Hertel</surname><given-names>J.</given-names></name></person-group>
<article-title>A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD</article-title>. <source>Clin. J. Am. Soc. Nephrol.</source>
<volume>9</volume>(<issue>4</issue>), <fpage>705</fpage>&#x02013;<lpage>712</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24458078</pub-id></mixed-citation></ref><ref id="bibr110-58841"><label>[110]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>N</given-names></name><name><surname>Cahill</surname><given-names>J</given-names></name><name><surname>Rajasekaran</surname><given-names>S</given-names></name><name><surname>Kovey</surname><given-names>K.</given-names></name></person-group>
<article-title>Ferumoxytol infusion in pediatric patients with gastrointestinal disorders: First case series</article-title>. <source>Ann. Pharmacother.</source>
<volume>45</volume>(<issue>12</issue>), <fpage>e63</fpage>.<pub-id pub-id-type="pmid">22116997</pub-id></mixed-citation></ref><ref id="bibr111-58841"><label>[111]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wankhede</surname><given-names>M</given-names></name><name><surname>Bouras</surname><given-names>A</given-names></name><name><surname>Kaluzova</surname><given-names>M</given-names></name><name><surname>Hadjipanayis</surname><given-names>CG</given-names></name></person-group>
<article-title>Magnetic nanoparticles: An emerging technology for malignant brain tumor imaging and therapy</article-title>. <source>Expert Rev. Clin. Pharmacol.</source>
<volume>5</volume>(<issue>2</issue>), <fpage>173</fpage>&#x02013;<lpage>186</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22390560</pub-id></mixed-citation></ref><ref id="bibr112-58841"><label>[112]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hildebrandt</surname><given-names>B</given-names></name><name><surname>Wust</surname><given-names>P</given-names></name><name><surname>Ahlers</surname><given-names>O</given-names></name><etal/></person-group>
<article-title>The cellular and molecular basis of hyperthermia</article-title>. <source>Crit. Rev. Oncol. Hematol.</source>
<volume>43</volume>(<issue>1</issue>), <fpage>33</fpage>&#x02013;<lpage>56</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">12098606</pub-id></mixed-citation></ref><ref id="bibr113-58841"><label>[113]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wust</surname><given-names>P</given-names></name><name><surname>Hildebrandt</surname><given-names>B</given-names></name><name><surname>Sreenivasa</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Hyperthermia in combined treatment of cancer</article-title>. <source>Lancet Oncol</source>. <volume>3</volume>(<issue>8</issue>), <fpage>487</fpage>&#x02013;<lpage>497</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">12147435</pub-id></mixed-citation></ref><ref id="bibr114-58841"><label>[114]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johannsen</surname><given-names>M</given-names></name><name><surname>Gneveckow</surname><given-names>U</given-names></name><name><surname>Taymoorian</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: Results of a prospective phase I trial</article-title>. <source>Int. J. Hyperth.</source>
<volume>23</volume>(<issue>3</issue>), <fpage>315</fpage>&#x02013;<lpage>323</lpage> (<year>2007</year>).</mixed-citation></ref><ref id="bibr115-58841"><label>[115]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maier-Hauff</surname><given-names>K</given-names></name><name><surname>Rothe</surname><given-names>R</given-names></name><name><surname>Scholz</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: Results of a feasibility study on patients with glioblastoma multiforme</article-title>. <source>J. Neurooncol.</source>
<volume>81</volume>(<issue>1</issue>), <fpage>53</fpage>&#x02013;<lpage>60</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">16773216</pub-id></mixed-citation></ref><ref id="bibr116-58841"><label>[116]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maier-Hauff</surname><given-names>K</given-names></name><name><surname>Ulrich</surname><given-names>F</given-names></name><name><surname>Nestler</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme</article-title>. <source>J. Neurooncol.</source>
<volume>103</volume>(<issue>2</issue>), <fpage>317</fpage>&#x02013;<lpage>324</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">20845061</pub-id></mixed-citation></ref><ref id="bibr117-58841"><label>[117]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumine</surname><given-names>A</given-names></name><name><surname>Takegami</surname><given-names>K</given-names></name><name><surname>Asanuma</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>A novel hyperthermia treatment for bone metastases using magnetic materials</article-title>. <source>Int. J. Clin. Oncol.</source>
<volume>16</volume>(<issue>2</issue>), <fpage>101</fpage>&#x02013;<lpage>108</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">21373775</pub-id></mixed-citation></ref><ref id="bibr118-58841"><label>[118]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mamiya</surname><given-names>H.</given-names></name></person-group>
<article-title>Recent advances in understanding magnetic nanoparticles in AC magnetic fields and optimal design for targeted hyperthermia</article-title>. <source>Journal of Nanomaterials</source>
<volume>vol. 2013</volume> (<year>2013</year>).</mixed-citation></ref><ref id="bibr119-58841"><label>[119]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>E.</given-names></name><name><surname>Kircher</surname><given-names>M. F.</given-names></name><name><surname>Koch</surname><given-names>M.</given-names></name><etal/></person-group>
<article-title>Dynamic magnetic fields remote-control apoptosis via nanoparticle rotation</article-title>. <source>ACS Nano</source>
<volume>8</volume>(<issue>4</issue>), <fpage>3192</fpage>&#x02013;<lpage>3201</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24597847</pub-id></mixed-citation></ref><ref id="bibr120-58841"><label>[120]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riedinger</surname><given-names>A.</given-names></name><name><surname>Guardia</surname><given-names>P.</given-names></name><name><surname>Curcio</surname><given-names>A.</given-names></name><etal/></person-group>
<article-title>Subnanometer local temperature probing and remotely controlled drug release based on azo*functionalized iron oxide nanoparticles</article-title>, <source>Nano Lett.</source>
<volume>13</volume>(<issue>6</issue>), <fpage>2399</fpage>&#x02013;<lpage>2406</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23659603</pub-id></mixed-citation></ref><ref id="bibr121-58841"><label>[121]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunisaki</surname><given-names>J.</given-names></name><name><surname>Saito</surname><given-names>T.</given-names></name><name><surname>Yamada</surname><given-names>T.</given-names></name><etal/></person-group>
<article-title>A possibility of hyperthermia using MRI equipment</article-title>. <source>Conf. Proc. IEEE Eng. Med. Biol. Soc.</source>
<volume>1</volume>, <fpage>6373</fpage>&#x02013;<lpage>6375</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">17945962</pub-id></mixed-citation></ref><ref id="bibr122-58841"><label>[122]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantillon-Murphy</surname><given-names>P.</given-names></name><name><surname>Wald</surname><given-names>L. L.</given-names></name><name><surname>Zahn</surname><given-names>M.</given-names></name><name><surname>Adalsteinsson</surname><given-names>E.</given-names></name></person-group>
<article-title>Proposing magnetic nanoparticle hyperthermia in low-field MRI</article-title>. <source>Concepts in Magnetic Resonance Part A</source>
<volume>36A</volume>(<issue>1</issue>), <fpage>36</fpage>&#x02013;<lpage>47</lpage> (<year>2010</year>).</mixed-citation></ref><ref id="bibr123-58841"><label>[123]</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jiles</surname><given-names>D.</given-names></name></person-group>
<source>Intzroduction to Magnetism and Magnetic materials</source>. <publisher-name>CRC Press</publisher-name>.</mixed-citation></ref><ref id="bibr124-58841"><label>[124]</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Coey</surname><given-names>JMD</given-names></name></person-group>
<source>Magnetism and Magnetic Materials</source>. <publisher-name>Cambridge University Press</publisher-name>
<year>2009</year>.</mixed-citation></ref><ref id="bibr125-58841"><label>[125]</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Thanh</surname><given-names>NT</given-names></name></person-group>
<source>Magnetic Nanoparticles: From Fabrication to Medical and Clinical Applications</source>. <publisher-name>CRC Press</publisher-name>
<year>2011</year>.</mixed-citation></ref><ref id="bibr126-58841"><label>[126]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weissleder</surname><given-names>R</given-names></name><name><surname>Nahrendorf</surname><given-names>M</given-names></name><name><surname>Pittet</surname><given-names>MJ</given-names></name></person-group>
<article-title>Imaging macrophages with nanoparticles</article-title>. <source>Nat. Mater.</source>
<volume>13</volume>(<issue>2</issue>), <fpage>125</fpage>&#x02013;<lpage>138</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24452356</pub-id></mixed-citation></ref></ref-list></back></article>